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Sinus floor elevation (SFE) may be required for implant placement in the severely 
resorbed posterior maxilla. Although often successful, autologous bone grafting 
requires a donor site and may lose substantial volume while remodelling. Bone 
replacement grafting (BRG) materials were developed to overcome these limitations. 
This study investigated three novel grafting materials:  1) equine collagen cone (CN), 
2) equine collagen cone filled with biphasic calcium phosphate particles (CO), 3) 
deproteinized bovine bone particles coated with polylactic acid and poly ε -
caprolactone copolymer (SB). These were compared with the most commonly-used 
bovine bone BRG, Geistlich Bio-Oss® (BO).  
Methods  
The extra-oral access sinus grafting model from Haas et al. (1998) was used in 11 cross-
bred female sheep. Two experimental sites on each side of the animal were prepared. 
CN, CO, SB, BO were each placed through separate 10 mm access window in the antral 
wall, under the elevated Schneiderian membrane. BO sites were covered with a porcine 
collagen membrane (Geistlich Bio-Gide®), while for CO, SB, BO sites the equine 
collagen membrane (RESORBA PARASORB®) from the manufacturer of these 
experimental materials was used. 
The animals were euthanised after 16 weeks. New bone, residual graft particles and 






One sheep did not survive the surgery. All sites in remaining ten sheep healed 
uneventfully. The CN and SB grafting materials resorbed completely and failed to form 
new bone. BO and CO particles were bridged by the new bone, the new bone fraction 
was 10% (±9%) for BO and 4% (±5%) for CO. The differences were not statistically 
significant. 
Conclusions 
CN and SB cannot be recommended for sinus grafting, based on this model.  
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Chapter 1. Introduction and literature review 
Implant-supported prostheses have revolutionized dentistry by providing a 
predictable and functional fixed treatment option for missing teeth. Implants require 
an adequate volume and quality of bone to be successfully placed and integrated. The 
posterior maxilla was demonstrated to be the most challenging site for implant 
survival1-5. The reasons for reduced survival of implants in posterior maxilla may be 
related to the macroscopic and microscopic anatomy of posterior maxilla, namely: 
reduced quantity of bone due to maxillary sinus pneumatization and edentulous ridge 
resorption, inadequate quality of bone, and greater occlusal loading upon the implants. 
Sinus floor elevation (SFE) procedures were developed to overcome these challenges.  
SFE are usually making use of grafting materials to guide bone repair and produce 
new living extra-skeletal bone in the site of future implant placement. Extensive body 
of research has been accumulated for different types of grafting materials and surgical 
techniques. New grafting materials are expected to be cheaper, more effective in 
guiding new bone formation or to have superior handling properties. 
Histomorphometry is the gold standard to assess bone healing in the grafted sinus. 
The fractions of residual graft, new bone and soft tissue can only be reliably assessed 
by histomorphometry. Human and animal studies concerning the healing of graft 
materials within the maxillary sinus have been carried out using histomorphometric 
analysis 6-8. 
This study was designed to evaluate performance of three novel grafting materials 
against a positive control in a sheep model. The histologic and histomorphometric 




1.1 The need for sinus grafting 
1.1.1 Sinus pneumatization  
The maxillary sinus of an infant is occupied by crypts of developing teeth and has little 
“free” space. Sinus air space growth accompanies the eruption of maxillary teeth. At  
12-13  years, the  sinus  floor  is  level  with the nasal floor, and at the age of 20, after 
completion of tooth eruption, the sinus floor reaches an average of 5 mm inferior to the 
nasal floor9. Maxillary sinuses demonstrate remarkable variability in size and wall 
thickness10, yet in some individuals, “physiologic” pneumatization leaves the roots of 
maxillary teeth with nothing but lamina dura and a thin layer of mucosa within the 
sinus10. The reasons for the differences in pneumatization are poorly understood. 
Heredity11, positive air pressure12, pneumatizing drive of the mucus membrane12, 
craniofacial configuration13, growth hormones13, and sinus surgery10 were identified as 
factors that may influence maxillary sinus pneumatization. 
Multiple studies describe late recommencement of the pneumatization in adults that 
have lost posterior maxillary teeth14-17. This late pneumatization was related to “disuse 
atrophy” of supporting bone after posterior tooth loss15, 16. Wolff’s law18 is a hypothesis 
which is used to describe the mechanism behind the change. According to Wolff, the 
bone tissue will continuously adapt itself to withstand mechanical stress. Teeth in 
function conduct stress onto supporting bone which responds by maintaining 
sufficient volume and orientation of trabeculae. Frost (1994)19 has further developed 
Wolff’s hypothesis: below the specified threshold of stress, the bone tissue remodelling 
leads to a decrease in mass to adjust to lower function levels. Sinus pneumatization in 
edentulous sites can be an example of such re-adjustment.  
Sharan and Madjar (2008)15 have inspected panoramic radiographs to measure post-
extraction sinus pneumatization and found that on an average 1.8-2.2 mm of sinus floor 
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resorption is expected after the extraction of maxillary teeth. However, in some cases, 
almost all bone in the sinus floor is lost, leaving only a paper-thin bony shell which is 
unable to support implants15, 20, 21.  
1.1.2 Alveolar ridge resorption 
The vertical dimension in the posterior maxillary area is lost not only to receding sinus 
floor but also to the resorbing alveolar ridge. The alveolar bone is functionally 
dependent on teeth and consists of bundle bone. Wolff’s law that applies to the sinus 
floor can similarly be used for alveolar ridges. When the teeth are removed, the bundle 
bone is lost to remodelling. The alveolar ridge resorption occurs at a faster pace during 
the first 3-4 months after tooth extraction22, 23 and then slows significantly24; however, 
the resorption may continue for a prolonged period of time.  
The combination of sinus pneumatization and alveolar ridge resorption may lead to 
the insufficient bone quantity to support implants in the posterior maxilla. A minimum 
of 3-5 mm of vertical dimension was recommended to achieve primary implant 
stability25-27. However, Peleg et al. (2006) reported cumulative survival of 97.9% of 2,091 
implants placed in 1-2 mm residual bone28. These implants were placed concomitant 
with sinus grafting by a very experienced practitioner using strict placement protocol. 
The need for primary stability was addressed by the authors, who stated that “…initial 
stability was obtained by meticulous condensation of the particulated bone graft 
around the implants. This condensation was possible due to direct visualization of the 
entire grafted compartment. The wide window opening was essential”28. 
Thus, sinus grafting can be used to manage insufficient bone volume by expanding the 
vertical and horizontal dimensions of the supporting bone prior to or at the time of 
implant placement29.  
1.1.3 Inadequate quality of maxillary bone 
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While the volume of bone is essential to support an implant, the biomechanical 
properties of the recipient site play an important role as well30. 
Various classifications were developed to describe the biomechanical properties or 
bone quality of the recipient site31. The first classification of bone quality still in 
extensive use today was developed by Lekholm and Zarb in 198532. The authors used 
radiography to describe the bone quality and quantity (Table 1-1). This classification 
was validated in multiple studies: for correlation with CT Hounsfield units33-35, for 




Table 1-1 Lekholm and Zarb classification  
Bone type Description Illustration 
Type Ⅰ Almost the entire bone is composed of 
homogenous compact bone 
 
Type Ⅱ Thick layer of compact bone surrounds a core of 
dense trabecular bone 
 
Type Ⅲ Thin layer of cortical bone surrounds a core of 
dense trabecular bone 
 
Type Ⅳ A thin layer of cortical bone surrounding a core 
of low-density trabecular bone of poor strength. 
 
Adapted from Lekholm and Zarb (1985)32 
Lekholm and Zarb32 distinguished the types of bone by using Roman numerals, but 
some studies36 refer to them using D (for density) and Arabic numerals, for example, 
Type Ⅰ may be referenced as D1 bone quality and type Ⅳ – D4.  
Multiple studies1, 30, 38, 39 reported higher chances of failure for the implants that are 
placed in poor-quality bone with the thin cortex and low-density trabeculae (Type Ⅳ 
bone). Histomorphometric and CT analysis showed that the posterior maxilla has a 
lower mineralized content, reduced trabecular thickness and density40-43. The poor 
quality of bone is thought to impact the survival rate of the implants placed in posterior 
maxilla, which is the lowest among all the oral implantation sites1, 38, 44, 45.  
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While mineralized bone content in type Ⅳ quality natural bone has been demonstrated 
to be 28%46, the mineralized bone content in grafted sites varied between 28.3% (grafted 
with CaCO3) and 40.1% (grafted with autologous bone), or in Lekholm and Zarb’s  
classification, type Ⅳ to type Ⅲ bone quality36. 
Thus, after grafting, the bone quality remains poor or may improve only slightly. 
However, as the bone remodels around implants, the bone-to-implant contact can 
increase – figures of 60-80% have been reported47, 48. The remaining particles of the graft 
don’t seem to affect bone-to-implant contact formation49-54.  
1.1.4 Occlusal loading and stress distribution 
Reduced quantity and quality of bone in posterior maxilla can be detrimental to both 
primary osseointegration of the implant and long-term survival under occlusal 
loading. 
Post-insertion stability of the implant is required for osseointegration to occur. 
Cameron et al. (1973)55 introduced the concept of threshold micromovement of the 
implant using porous Vitalium staples in an unstable osteotomy sites in. The 
researchers stated that displacements of 150 µm and more should be considered as 
excessive and will cause fibrous implant encapsulation. Hence, mechanical loading 
was thought to be a critical factor determining the long-term survival of implants5, 56. 
In engineering terms, the implant acts as a bar elastically supported by the surrounding 
bone. According to finite element analysis, when the physical stresses exceed a certain 
physiologic threshold, the bone-implant interface could fail57. Clinically, the excessive 
local stress around an implant was associated with marginal bone loss and 
histologically – with pressure necrosis of the host bone and microfractures of 
trabeculae58, 59. Some earlier studies stated that overloading an implant may result in 
complete loss of osseointegration of implants, even after a long time of service5, 60.  
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However, since the earlier days of dental implantology, a considerable body of 
evidence has accumulated61-64, linking the peri-implant tissues’ inflammation and 
progressive marginal bone loss that may lead to implant failure. Most bone loss around 
teeth (periodontitis) is regarded as a biofilm-mediated infection and, analogously, some 
researchers believe that bone loss around an implant also constitutes an infectious 
process (peri-implantitis)65-67. The term peri-implantitis has been firmly based in the 
theory and practice of implant therapy, albeit its clinical definition is still disputed62, 63, 
68, 69.  
Stress applied to the implant is concentrated around its neck as demonstrated with 
mathematical models and finite element analysis70, 71. However, in posterior maxilla the 
cortical plates can be very thin or non-existent, thus larger forces may be propagated 
to the apical areas72. In addition to that, the occlusal forces are increased five- to ten-
fold in posterior regions of maxilla as opposed to anterior regions29. 
While unable to improve the bone quality, sinus grafting aims may improve stress 
distribution by providing a larger volume of bone to place longer and wider implants 
in positions more suitable for the prosthesis. Finite element analysis study has revealed 
that even though the maximum stress is applied to the cervical area of the implant, 
sinus grafting in the apical regions reduces intra-bony stress by 30%; displacements of 
the implant tip during loading can be reduced by up to 32%73.  
1.1.5 Conclusion 
Insufficient bone volume is a frequent problem encountered in the rehabilitation of the 
edentulous posterior maxilla. The bone available for implant placement may be limited 
by pneumatization of the maxillary sinus, together with the loss of alveolar bone 
height. Posterior maxilla consists of sparsely trabeculated bone with mediocre 
mechanical properties and limited repair capacity. Increased occlusal forces are 
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applied to the posterior maxilla compared to the anterior portion, placing primary 
implant stability and initial osseointegration of the implants in posterior maxilla at risk. 
While sinus grafting cannot improve the bone quality by a great margin36, it can 
provide more bone volume to support implants. Systematic reviews of the relevant 
literature have demonstrated that the sinus floor augmentation procedure is highly 
successful and well-documented; the use of modern moderately-rough implants 




1.2 Biology of bone repair and graft incorporation 
The desired outcome for sinus grafting procedures is graft incorporation into and 
replacement by the vital bone while maintaining the volume. The process whereby the 
grafted material is incorporated into the surrounding natural bone has been described 
as consolidation. During graft consolidation, the host blood vessels sprout into the 
grafted area, and osteogenic cells form the new bone. This process is a variation of 
normal bone repair and remodelling. Certain properties of the grafting material can 
facilitate graft consolidation. Among these properties, osteoconduction, 
osteoinduction and osteogenesis are commonly cited78. 
1.2.1 Bone regeneration and remodelling 
To accurately describe the graft consolidation in the sinus floor, the normal bone repair 
and remodelling process is to be explained. The bone forms and repairs via two 
principal routes: intra-membranous and endochondral. 
1.2.1.1 Intramembranous and endochondral bone formation 
When the word “bone” is used, it is important to distinguish whether it describes the 
bone as an organ (with specific location, anatomy, cartilage, marrow and periosteum) 
or as tissue type. Bones as organs develop embryonically using two distinct 
mechanisms:  
a) The intramembranous bone formation is mediated by the inner periosteal 
osteogenic layer with bone synthesized initially without the mediation of a 
cartilage phase. Bones of the skull are formed by the intramembranous 
mechanism. 
b) The endochondral bone formation describes the synthesis of bone on a 
mineralized cartilage scaffold after epiphyseal and physeal cartilage have 
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shaped and elongated the developing organ. Long bones (including ileum) are 
formed by the endochondral mechanism. 
The repair of fractured or injured adult bones can also be intramembranous or 
endochondral. The subcutaneous demineralized bone matrix (DBM) grafts sourced 
from femoral bone (formed by endochondral ossification) induce endochondral 
ossification79, while DBM sourced from calvarium (formed by intramembranous 
ossification) ossify by the intramembranous mechanism80. The endochondral bone 
repair can also occur when the site is not mechanically stable81.  
The difference in these mechanisms of bone formation may play a significant role when 
developing the experimental model. The rabbit femur and tibia have been widely used 
as the animal model in implantology82-84. However, the difference in bone formation 
and physiology may have an impact on the applicability of the results to intra-
membranous maxilla and mandible85. 
Autologous grafts retain the mechanisms of healing and repair of the bones they were 
harvested from80, 86. The endochondral grafts (tibia, iliac crest) lost more volume 
postoperatively, compared to intra-membranous grafts (calvarium, intraoral sites)86, 87. 
1.2.1.2 Stages of bone repair 
After an injury, the bone repair starts with blood clot formation and platelet 
aggregation. The platelets and endothelial cells produce cytokines, including TGF-β, 
vascular endothelial growth factor (VEGF), and platelet-derived growth factor 
(PDGF)88. The cytokines set off a rigorously controlled multi-stage inflammatory 
response, during which the neutrophil, the macrophage and, finally, the lymphocyte-
predominant cell populations migrate into the area, subdue the invading micro-
organisms, phagocytose the debris and induce bone repair89.  
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Stimulated by angiogenic signal molecules, blood vessels sprout into granulated tissue. 
These signal molecules are released earlier from the platelets and later from osteogenic 
cells and macrophages90. Hypoxia in the grafted area is by itself a potent stimulating 
factor for angiogenesis91, 92.  
After the vascularization of the repairing site, the osteogenic cells start to form new 
bone. The exact origin of osteogenic cells in maxillary bone repair is unknown. They 
may migrate via the blood supply or proliferate from locally present stem cells, or 
both93-96. The Schneiderian membrane (SM) may also contain osteoprogenitor cells: in 
a series of in-vitro and in-vivo studies in human subjects, Srouji et al. (2009,2010)97, 98 
successfully retrieved osteoprogenitor cells from the sinus membrane samples. These 
cells produced histologically evident bone at ectopic sites following transplantation 
into mice. However, it’s not clear whether sinus membrane-derived osteoprogenitor 
cells play a significant role in the new bone formation after sinus floor elevation. For 
example, after SFE and implant placement in monkeys, no new bone formed 
underneath SM around apical implant surfaces99.  
The formation of bone can be divided into three stages100: 
1. Woven bone formation: In an environment where no pre-existing bone 
(intramembranous mechanism) or cartilage matrix (endochondral mechanism) is 
present, undifferentiated mesenchymal cells differentiate into pre-osteoblasts 
and then to osteoblasts that secrete bone matrix in all directions in a random 
array. The disorganized osseous tissue that forms is called woven bone due to 
its characteristic histologic appearance. 
2. Adaptation of bone mass to load: When a sufficient amount of woven bone has 
been synthesized to serve as a structural scaffold, osteoblasts array themselves 
in well-polarized fashion along the woven bone surface. Unlike the first stage, 
they start to secrete collagen fibrils only onto the pre-existing bone surface, not 
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circumferentially. The bone matrix that forms is organized in a parallel or 
lamellar orientation, and this type of bone is called lamellar bone. The lamellar 
bone resistance to stress is superior to that of the woven bone89. The rate of 
lamellar bone deposition in humans is 1-1.5 µm/day100.  
3. Adaptation of bone structure to load (bone remodelling): During the third 
stage, after the lamellar bone is formed, the bone remodelling adapts the bone 
trabecular structure to stress. The remodelling is done by organized resorption 
and apposition in a conglomerate of cells, which Frost in his book named the 
basic multicellular unit (BMU)101. In BMU the cutting cone of osteoclasts 
advances with a speed of about 50 µm per day and is followed by a vascular 
loop, accompanied by perivascular osteoprogenitor cells101. About 100 µm 
behind the osteoclasts, the osteoblasts line up on the wall of the resorption canal 
and begin to deposit concentric layers of lamellar bone101. The unit of bone, 
formed by BMU, is called osteon. 
1.2.1.3 Regulation of bone remodelling and repair 
In the 1960s the prevalent concept of bone regulation was the metabolic one. A variety 
of metabolic factors, vitamins and hormones indeed influence the bone formation and 
remodelling. For example, the thyroid hormone, vitamin D, and calcitonin all serve as 
regulators102. This view, however, can’t explain the adaptation to stress, a unique bone 
property. Harold Frost, in a series of publications, hypothesized that the adaptation to 
stress is the primary regulatory factor in bone formation, remodelling and resorption103, 
104. This hypothesis, which Frost named the ‘Mechanostat Theory’, explains that the 
mechanical load which is applied to the bone matrix and cells causes them to generate 
signals which they and other cells can respond to. The signalling depends on the load 
magnitude, and the stress thresholds for changes in signals are genetically determined. 
The key concept in bone adaptation to stress is the repair of the microfractures in 
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trabeculae by new osteons. Thus, the adaptation of the bone structure to load is 
regulated by the very load which is applied, according to the Mechanostat model. 
While the biological mechanism of this model is not entirely understood105, 106, it offers 
a convenient framework to understand the bone repair, remodelling and graft 
consolidation. 
The normal rate of bone remodelling wouldn’t allow for the efficient bone 
regeneration. However, after the bone is wounded, the bone forming and remodelling 
processes experience a transient burst which may last for more than two years29. This 
burst was named by Frost ‘Regional Acceleration Phenomenon’ (RAP)107, 108. The 
increased rate of remodelling helps in volumetric bone regeneration and adapting the 
newly formed bone to stress via trabecular orientation109.   
1.2.1.4 Critical size defects 
The bone repair process depends on the size of the defect and the stability of the 
wound. Smaller defects can repair by direct bridging with Haversian channels, while 
larger defects require more complex staged repair as described in the section 1.2.1.2. 
Defects which cannot be fully regenerated with bone, but instead are filled with fibrous 
connective tissue, are called critical size defects. The critical size varies between species 
and bone sites110. For the rat skull, the critical defect size was identified as 5 mm, while 
for the sheep, cranial defects were 22 mm111.  
The critical size defect models have been used extensively in the orthopaedic research 
of bone regenerative materials. The tested materials in orthopaedic research are 
required to prove their effectiveness by bringing the critical size defects to osseous 
healing112. In sinus grafting, however, the role of grafting material is mostly the 
maintaining of space and providing the surface for the formation of the new extra-
skeletal bone (explained in more detail in section 1.2.2). The size of the surgical access 
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window in a lateral approach for sinus grafting is usually less than 20 mm. The healing 
of the access window is not considered to be a primary outcome, therefore it is not 
assessed in depth; however, full healing was observed at 6 months in monkeys 113. 
 
 
1.2.1.5 Osteogenesis in non-grafted sinus sites 
The elevation of the Schneiderian membrane (SM) creates a space which is 
immediately filled by a blood clot. Experimental animal data113-116 and clinical reports 
in humans117, 118 have clearly demonstrated that new extra-skeletal bone formation 
occurred underneath the elevated SM without the use of a filler material.  
However, without a space-maintaining device, the blood clot will quickly resorb, the 
elevated SM will collapse and no new bone formation will happen119. Implants serving 
as space-maintainers may fail to prevent the SM collapse120, 121. Sinus grafting may offer 
a more predictable treatment modality if the grafting material poses no interference to 
normal formation of the new bone in the augmented site. Ideally, the grafting material 
will become incorporated and replaced by the recipient bone. 
1.2.2 Graft incorporation and remodelling 
Graft incorporation  includes the in-growth of new vasculature (angiogenesis), the 
formation of woven bone-graft complex, and remodelling of the integrated graft 
material and surrounding bone by BMUs29.  
The graft is a foreign body. It can be encapsulated in the connective tissue, rather than 
incorporated into the bone of the recipient site. To be incorporated, the grafting 
material needs not only to be biocompatible (non-toxic to cells) but also to allow 
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adherence of osteogenic cells and bone deposition directly onto the surface of the 
grafting material. 
1.2.2.1 Osteoconduction, osteoinduction, osteogenesis  
Originally, the term osteoconduction was coined in orthopaedic literature and was not 
related to bone grafting materials but rather to various orthopaedic implants. For 
example, osteoconduction is not possible in certain materials such as copper and 
silver122, but well documented on titanium implants69, 78. The difference between the 
materials lies in the ability of osteoblasts to adhere to their surface. Osteoblasts adhere 
to the grafting material not directly, but via proteins such as vitronectin, fibronectin 
and albumin that are adsorbed to the surface of the material from blood and extra-
cellular matrix123, 124. The graft-cell adhesion biochemistry is a complex and not entirely 
understood process, where surface topography, charge, wettability, pH and ionic 
composition of the graft all play a role125.  
The osteogenic cells are recruited to the site by biochemical factors. This recruitment 
process is sometimes called osteoinduction. The autologous bone grafts and 
demineralized bone grafts, such as DFDBA, are considered osteoinductive due to the 
presence of biochemical factors such as bone morphogenic proteins (BMPs). The 
surgical injury and normal bone repair produce sufficient amounts of osteoinductive 
factors to recruit previously undifferentiated bone cells78. However, agents, such as 
BMPs and platelet-rich plasma (PRP), have been added to grafting materials in an 
attempt to enhance bone formation within grafts with variable success126-128. Several 
reviews concerning the use of osteoinductive factors129-131 concluded that while 
demonstrating promising results in some studies, the addition of osteoinductive 
factors still lacks unequivocal evidence. 
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Osteoconduction and osteoinduction are sometimes used interchangeably to describe 
bone formation in the grafted area. It was indeed established that the topology of the 
surface of some grafting materials might induce osteogenic cell differentiation and 
proliferation, although the biological mechanism is not fully understood124, 132, 133.  
If the graft itself contains bone-forming cells which may produce new bone it may be 
argued that such a graft possesses osteogenic properties. It was established that some 
osteoprogenitor cells from autologous bone graft might survive the intraoperative 
manipulation and retain osteogenic potential134, 135. The origin of osteogenic cells at the 
sites of bone regeneration is not entirely clear. In the seminal work on a rat model, Ray 
(1972)135 demonstrated that autologous bone transplants might re-vascularize by 
anastomose creation to the blood vessels of the recipient bed as early as 2 days post-
transplantation. This reperfusion doesn’t prevent the necrosis of the existing 
osteocytes136, but some osteogenic cells survive and retain their osteogenic potential135. 
The surviving multipotential cells of the autologous graft and the migrating 
multipotential cells from the recipient site populate the necrotic marrow spaces; 
osteoblasts line the edges of the dead trabeculae and lay down a seam of osteoid, which 
eventually surrounds a central core of necrotic bone137. As the graft incorporation and 
fracture repair involve recruitment of progenitor cells from the blood stream81, 138, we 
may only speculate about the extent of the contribution of the surviving cells from the 
graft to the new bone formation and graft incorporation. 
1.2.2.2 Graft incorporation into viable bone 
1.2.2.2.1 Angiogenesis  
The incorporation of the graft into the recipient bone starts on the day of the procedure 
and depends on sufficient blood supply139. Bone is a metabolically active tissue 
supplied by an intraosseous vasculature with osteocytes positioned no more than 200 
µm from a capillary140, 141. The hypoxic necrosis of the central part of the graft happens 
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to stem cell grafts on engineered scaffolds90 as well as autologous bone transplants142. 
Driven by hypoxia and inflammation, the sprouting of new vessels starts within days 
from surgery92, 139.  
The vascularization of autologous grafts is different from the vascularization of non-
vital xenografts or alloplasts. The non-vital xenografts and alloplasts simply become 
incorporated into the granular tissue which has abundant vasculature. Capillaries 
serve not only as oxygen and nutrient suppliers but also as the pathway and the 
promoter for the pluripotential osteogenic cells. Osteogenesis is thought to happen 
along the vascular structures of the tissue92. 
The grafting material should possess interconnecting pores of sufficient size to allow 
for the ingrowth and interconnection of the capillary bed143, 144. The porosity of the 
material is even more important for the ingrowth of bone. A pore size of 100 µm is 
often cited as a minimum requirement for bone ingrowth145-147. Some studies report that 
volume and rate of integration depend on the pore size148, 149. Other researchers 
promote the importance of additional structural parameters, such as pore morphology, 
percent porosity, and pore connectivity150, 151. The ideal porosity and the crystalline 
microstructure of the grafting material remain to be identified. 
1.2.2.2.2 Osteogenesis  
By stabilizing the blood clot and by providing a cell-adhesive osteoconductive surface, 
even the non-vital grafting material can guide new bone into a grafted area152. The 
osteoconduction by the grafting material may result in bone regeneration of a non-
healing, critical size defect, when woven bone sprouts into the vascularized space 
between the particles of bone substitute153, 154. As a result of graft incorporation, the 
particles of grafting material become connected by the newly formed bone74. As bone-
graft complex gains some structural durability, the stress which is applied to it can 
theoretically control the remodelling, according to Frost’s Mechanostat theory104.  
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A series of animal experiments have demonstrated that after sinus grafting, the new 
bone is more abundant near the bony walls of the sinus than on the ‘far side’ of the 
grafted area, in the proximity of the SM7, 155-157. Some authors have used the term 
‘consolidation gradient’ to explain the differences155. The consolidation gradient may 
suggest that after sinus grafting, osteogenic cells migrate from the existing bone wall 
and are guided by osteoconductive properties of the grafting material towards the SM. 
1.2.2.3 Graft remodelling  
Depending on the chemical and physical structure, the grafting material may degrade 
after the implantation. In general, two pathways exist for resorption of the material: 
1. Haversian remodelling: Materials containing crystalline hydroxyapatite may 
be resorbed in the same manner as the bone, by osteoclasts. Histologically, 
osteoclastic resorption is characterised by the presence of multi-nuclear cells in 
lacunae on the surface of the material158. Haversian remodelling results in 
creeping substitution by natural bone. 
2. Non-osteoclastic chemical breakdown: This mechanism leads to loss of 
mineralized tissue in the grafted area. The chemical breakdown mechanism 
depends on the acidity of the environment, and the chemical composition and 
the porosity of the material159, 160. 
Ideal grafting material will be completely substituted by the natural bone while 
retaining the mineralized tissue volume. These appear to be contradictory demands: 
the materials which are easily replaced by bone tend to lose a significant portion of 
their volume 161, while space-maintaining materials tend to remain indefinitely in the 
grafted area 162.  
1.2.3 Speed of consolidation 
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As in the normal bone repair, the sinus floor elevation (SFE) will activate the regional 
acceleration phenomenon (RAP) manifesting in rapid vascularization, bone-graft 
complex formation, and maturation of the grafted area163. The graft maturation time is 
significant for implant treatment planning. The woven bone starts to form under 
elevated sinus as early as 4 days post-op 164. The initial speed of bone ingrowth into the 
graft may be as fast as 1 mm per week29. However, calculations based on 
histomorphometric analysis of samples taken at four time-points from human grafted 
sinuses suggested the average  rate of 1 mm bone ingrowth per month165. A review of 
histological studies in humans166 has concluded that mineralized bone volume changes 
insignificantly between 6 months and 12 months of healing. Kohal et al. (2015)167 in a 
recent publication state that even after 3 months of healing, there is only minor 
addition of new bone.  
In the systematic review of clinical outcomes76, the healing periods ranged between 3-
10 months after grafting, prior to implant placement, and up to 10 months after implant 
placement. The healing periods did not affect implant survival for any of the grafting 
material, which suggests that either: 1) Healing is by-and-large is finished by 3 months 
post-grafting or 2) Bone mineralization after 3 months is sufficient to support implant 
stability and osseointegration. 
1.2.4 Conclusion 
Grafting alters the natural repair of bone by stabilizing the blood clot, maintaining the 
space for the new bone ingrowth, and by providing osteoconductive surfaces for 
osteogenic cells’ adherence. Osteoconductive, osteoinductive and osteogenic 
properties of the graft may all influence the outcome of grafting. The porosity and 
crystallinity of the graft are important to allow the vascularization of the area.  
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The osteogenic cells in SFE arrive from the direction of antral walls, and the new bone 
formation creates a gradient of consolidation towards the Schneiderian membrane. 
With time, the particles of the graft become part of graft-bone complex. This complex 
undergoes remodelling, and the graft may be substituted by the recipient bone. The 
graft resorption and substitution depends on the chemical and physical structure of 




1.3 Grafting materials 
1.3.1 Autologous bone grafts 
Autogenous bone is harvested directly from the patient. Common harvesting sites are 
the retromolar region, the chin, or the iliac crest168. The harvested bone may be 
cancellous, cortical or mixed morphology and in block or particulate form depending 
on the harvesting technique.  
Autologous bone grafts (ABG) possess osteoconductive, osteoinductive and osteogenic 
properties. As result of consolidation, the autologous grafts are replaced by the viable 
new bone; the process is known as creeping substitution137.  
There are, however, serious drawbacks with ABG. First, ABGs are harvested from the 
additional surgical site, which leads to increased site morbidity, patient discomfort, 
and sometimes, additional complications169-171. Second, when used for sinus floor 
elevation (SFE), ABG may lose 20-50% of its initial volume during the first year74, 172-174.  
The unpredictable graft resorption and the donor site morbidity have led the industry 
to develop an array of bone substitution materials. 
1.3.2 Allografts 
Allografting is the process by which bone is transferred between two genetically 
dissimilar individuals of the same species. Several methods are used to process human 
bone, including irradiation, physical debridement, ultrasonic or pulsatile water 
washes, ethanol treatment, and antibiotic soaking175. Freeze-dried bone allograft 
(FDBA) and demineralized freeze-dried bone allograft (DFDBA) are the most 
commonly used allografts for SFE. Both FDBA and DFDBA are considered to be 
osteoconductive and osteoinductive143; however, the osteoinductive potential was  
inferior to that of ABG137. 
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Histologically, allografts demonstrated creeping substitution by the bone, with the 
histomorphometric outcomes similar to those of xenografts (discussed in the section 
1.3.3) in terms of new bone formation and the residual graft resorption176. Similarly to 
ABG, a substantial loss of volume was reported for allografts177. 
The principal concern with allografts is viral disease transmission, including hepatitis 
C, hepatitis B, and human immunodeficiency virus (HIV). The Sinus Conference in 
1996 concluded that DFDBA is not an appropriate bone substitute because of the risk 
of disease transmission and pronounced resorption178. Allografts enjoy popularity in 
the United States of America, where strict donor screening programs were 
employed137, but their use is restricted in Europe by regulation143.  
1.3.3 Xenografts 
Xenografts for sinus floor elevation consist of mineral derived from animals (usually 
from cows or pigs) or calcified exoskeletons of marine coral or algae. The organic 
components of the xenografts are removed by processing, leaving the macro- and 
microporous structure, which closely resembles human cancellous bone and supports 
vascularization and new bone ingrowth. The exact process of manufacturing for each 
material is a commercial secret and is not published in detail. The osteoconductive and 
resorptive properties of xenografts that were produced using different protocols may 
vary179.  
For the animal-derived products, the concerns have been raised about the possibility 
of transmitting prion diseases180; however, no cases of such a transmission were 
recorded. In contrast, two cases of HIV transmission through allografts were 
reported143.  
Xenografts were found to be osteoconductive in the one-wall calvarial defect animal 
model152, critical size defect repair model181, and in human sinus floor augmentations182.  
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Unlike the ABGs, the xenografts do not necessarily undergo complete resorption and 
substitution by the host bone. Although some algae-derived products will completely 
biodegrade as early as 8 weeks179, the bovine-derived xenograft was present years after 
implantation162, 183-185. Histologic long-term investigations of biomaterial degradation in 
human participants are scarce and mostly confined to case series162, 185-187, which show 
partial resorption of the biomaterial. In a recent longitudinal trial in humans, the 
fraction of DBBM decreased from 37% down to 20% between 5 to 11 months of healing 
reaching statistical significance188.  
As described in section 1.3.1, the loss of volume by the graft is a primary concern when 
using the autologous bone for SFE172, 189. Thus, slow- or non-resorbing grafts may be 
especially suited for SFE where long-term space maintenance is required190, 191. In a 
recent systematic review173 authors have calculated a cumulative volumetric reduction 
of slow-resorbing xenografts and alloplasts placed in the sinus to be 18-23%, if used 
alone or in combination with ABG. This is a considerable improvement compared to 
45% of volume loss by pure AB grafts173 . Some authors advocate the use of a 
combination of osteoinductive autologous bone graft and osteoconductive non-
resorbing xenograft to achieve grafting site stability together with higher new bone 
formation192-194. However, authors of a systematic review190 could not accept, nor reject 
this claim.  
The extent of replacement of the xenograft by the bone may depend on the way the 
material was manufactured – specifically, high-temperature deproteinization. 
Temperatures which exceed 1000˚C cause sintering of the crystalline structure of 
hydroxyapatite and reduction of its porosity and micro-roughness195. The effect of 
sintering is well-known for synthetic alloplastic materials – it delays the resorption of 
the synthetic hydroxyapatite196. In contrast, recent randomized controlled studies with 
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human participants have failed to demonstrate a statistically significant difference of 
replacement-resorption between sintered and non-sintered xenografts197, 198. 
1.3.4 Alloplasts 
Alloplasts are a diverse group of completely synthetic grafting materials. Like 
xenografts, they stabilize the wound and provide an osteoconductive scaffold for the 
new bone formation. Their main advantage is safety, in terms of disease transmission. 
Also, for patients who are concerned with human-derived or animal-derived products, 
alloplasts may be the only acceptable grafting material. 
The other reason for the development of alloplastic materials is the theoretical 
possibility of adjusting their chemical and physical characteristics to suit a specific 
clinical demand. For example, the manufacturers of calcium phosphate ceramics are 
able to control  macro- and microporosity as well as inter-connectedness of their 
products199. While  biomaterial science has made considerable advances, ideal 
characteristics for the alloplastic material are yet to be identified161. As for physical 
properties, although faster ingrowth is favoured by a more porous, interconnected 
structure, denser ceramics have better mechanical integrity200.  
Alloplasts for sinus grafting in humans were investigated in case studies201-203,  
controlled trials204-207 and systematic reviews208-210. It appears that histologic and clinical 
outcomes of SFE using some alloplasts are comparable to those of xenografts. 
Calcium phosphate alloplasts received the most attention in research: non-resorbing 
hydroxyapatite (HA) and quickly-resorbing tricalcium phosphate (TCP) and their 
combination, biphasic calcium phosphate210. In a seminal work, Jensen et al. (2009) 
examined different HA/TCP ratios in the minipig mandibular defect model161. The 80% 
/ 20% and 60% / 40% HA/TCP ratios have demonstrated residual graft and new bone 
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formation comparable to that of DBBM (Bio-Oss®), while 20% / 80% HA/TCP ratio lost 
volume similar to ABG. All bone substitutes demonstrated less new bone than ABG.  
The concept of space-maintaining synthetic osteoconductive material for sinus grafting 
received support from a recent pilot study147. Two human participants received sinus 
augmentation with porous titanium granules in one sinus and DBBM in the 
contralateral sinus. The implants were placed after 9 months, and trephine biopsies 
were taken from the sites. The new bone formation was similar for both sinuses after 9 
months of healing147. In another case series with five human participants, the operators 
used a 0.3 mm poly-L-lactic acid (PLA) mesh reinforced with resorbable HA to 
suspend the SM in the elevated position211. At 6-9 months post-operation, the newly 
formed bone enabled insertion of implants 8.5-11.5 mm long. Trephine biopsies 
confirmed new bone formation histologically211.  
Reports of SFE using tissue-engineered constructs, either combined with growth 
factors or cultured cells, appear more and more in the literature. For a review see 
Larsson et al. (2016)212. The development of these conceptually novel materials began 
30 years ago. It was hindered by the complexity of the procedures, the costs and 
concerns over the neoplastic potential of growth factors and stem cells213; the 
engineered tissues are still unavailable for wider professional use today. 
1.3.5 Implants placed in the augmented sinus floor  
Sinus grafting aims to create more viable bone for implant placement. As it was stated 
in section 1.1.3, after graft consolidation the quality of the created bone corresponds to 
type Ⅳ bone, based on the Lekholm and Zarb classification36. Despite the seemingly 
inferior quality of augmented bone, the cumulative survival rate of moderately rough 
surface implants placed in the grafted sinus is more than 90%, similar to that of 
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implants placed in non-grafted posterior maxilla214. The implant osseointegration was 
shown to be independent of the grafting material that was used172.  
Implant osseointegration can be measured histologically as the percentage of bone-to-
implant contact (BIC) out of the total surface of the implant. BIC around implants in 
grafted sites was reported to be between 40% and 80%47, 48, 53, 215. Thus, the bone 
contacting implants was denser than the poor-quality bone present in the rest of the 
augmented site. In one study, implants were shown to have successfully 
osseointegrated in sites with NB content as low as 24% 216.  
However, if bone coating forming over implants is thin and not contributing to 
mechanical support, the BIC figure may be misleading. In a canine study, 50 µm 
lamellar bone coating was formed over titanium implant threads that contacted bone 
marrow of the cancellous bone217. This mechanically non-important layer may amplify 
the value of bone-to-implant contact to levels higher than those achieved in a cortical 
bone.  
On the other hand, BIC was positively correlated with implant torque-out tests82 and 
non-destructive stability tests such as ISQ218. According to Frost’s Mechanostat 
hypothesis19, the implant under occlusal loading will apply stress to the supporting 
bone; in this case, the increased BIC might be a result of adaptive bone remodelling.  
While histology provides an invaluable tool for research, the exact correlation between 
histologic parameters (new bone fraction, BIC), and implant success is yet to be 
elucidated. Esposito et al. (2010)219 in the systematic review stated that reporting 
histomorphometric bone-mineralised content alone is insufficient to draw clinically 





Autologous bone is the only grafting material possessing osteoinductive, 
osteoconductive and osteogenic properties. However, it is not the ideal for sinus floor 
elevation, as autologous bone requires an additional surgical site for harvesting and 
may lose substantial volume during consolidation.  
An array of biomaterials has been developed and tested. Currently, there is little 
evidence of the superiority of one type of biomaterial over another in terms of 
histologic outcomes or implant survival. The reason to develop new biomaterials for 





1.4 Sinus grafting procedures 
Boyne & James (1980) 220 and then Tatum (1986) 221 reported on their attempts at SFE. 
Since these early reports, a variety of SFE procedures have been developed. These 
procedures may differ by surgical protocol, timing, equipment, access and the use of 
grafting materials and barrier membranes. In this section, the principles of sinus 
grafting, along with variations in practice and alternatives to sinus floor elevation for 
implant placement, will be discussed. 
1.4.1 Maxillary sinus anatomy and its relevance to sinus grafting 
The maxillary sinus (MS) is an epithelium-lined space in the maxillary bone. In adults, 
it has a reverse pyramidal shape with a wider base being the roof of the orbit and the 
apex situated close to the roots of the first bicuspid tooth.  
The physiologic purpose for paranasal spaces in humans is not entirely understood; 
however, they may perform various functions. In his review, Drettner (1980)222 lists the 
following roles the MS might play in humans: 
1. Phonetic (sound resonance and transmission) 
2. Respiratory (air conditioning and pressure equalizing) 
3. Olfactory (reservoir of air may be utilized as reference to new olfactory stimuli) 
4. Static (reduced weight of the facial bones) 
5. Mechanical (shock absorbing in traumatic injuries) 
6. Thermal (heat insulating of the skull base) 
The sinus space anatomy varies between individuals. It can form either a singular 
space or several spaces, divided by septae223. Maxillary sinus septae were first 
described by Underwood in 1910224. It was speculated that septum gradually forms 
between two zones of alveolar bone resorption225. The presence of septae can pose 
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difficulty for surgical access, Schneiderian membrane elevation and grafting material 
placement220, 226. According to computerized tomography analysis, the septae is present 
in 29% of humans225. To date, there were no published reports about the frequency and 
morphology of MS septae in animals. Pre-surgical screening of sinus anatomy may be 
employed in animal SFE research to account for the possible septae, constrictions, 
vasculature or other unusual anatomical features of MS. 
The sinus floor in humans consists of dense lamellar bone. It can be smooth or uneven, 
depending on the position of the roots of maxillary teeth. With time, the teeth roots 
which protrude into the sinus space may become attached to only a paper-thin layer 
of cortical bone via the PDL15.  
The sinus space is lined with Schneiderian membrane (SM), which consists of a single 
layer of ciliated, columnar, respiratory epithelium covering lamina propria227. The 
lamina propria fuses with the underlying periosteum to form the mucoperiosteum, 
which is 0.13-0.5 mm thick in a healthy sinus227. After SFE, a transient swelling and 
inflammation of the membrane may be observed228. Using computerized tomography 
investigation, Makary et al. (2016)229 demonstrated that this swelling might reach up to 
7 mm after the first week, but then gradually decreases over the course of 12 months, 
dropping below 1 mm after 6 months of healing. Interestingly enough, the average 
thickness at 12 months post-op was lower than pre-op; the difference was statistically 
significant229.  
The average thickness of SM in goats and sheep is 2.03 mm and in pigs –  2.80 mm230; 
thicker membrane suggests less chance of perforations during SFE. 
The vascular supply of the sinus is provided by the posterior superior alveolar artery, 
inferior orbital artery, greater palatine artery, and sphenopalatine artery (branches of 
the maxillary artery, which is a continuation of the external carotid artery). The 
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vasculature exhibits multiple anastomoses between the supplying branches231. This 
abundant vascular architecture can be beneficial for post-operative healing after sinus 
interventions232. On the other hand, because severing 2.5 - 3 mm arteries can complicate 
surgery, a thorough pre-op investigation may be warranted233. In posterior maxilla, 70-
100% of blood supply originates from the periosteum234. Therefore, care must be taken 
not to compromise the blood supply when raising flaps for the lateral access. 
Innervation of the sinus is supplied by the superior, middle and anterior alveolar 
nerves, greater palatine nerve and infraorbital nerve235. The nerves accompany the 
veins and lymphatics of the sinus. Severing or damaging the nerves of MS during SFE 
was not reported in the literature; however, care must be taken to avoid compression 
of the infra-orbital nerve bundle while performing blunt dissection of the tissues29. 
The lateral walls of the sinus in humans consist of relatively thin bone, which may 
become even thinner (reaching 1.71 – 1.57 mm ) when the maxillary teeth are lost236. 
Thus, care must be taken not to unintentionally perforate the bone and the underlying 
SM when gaining access to the MS through its lateral wall. In animals, the lateral walls 
of the sinus may be thicker or thinner than human ones, depending on the animal230 
1.4.2 Clinical procedures and variations in practice 
The aim of the first reported SFE was to reduce the size of posterior maxilla for denture 
placement, as the paper-thin bone did not allow for the alveoplasty220. Today, the sinus 
space is entered routinely to increase the bony support for dental implants. A variety 
of techniques have been developed for sinus grafting. As my study employs one 
specific protocol, it’s worth outlining the main variations in clinical practice of SFE. 
 
1.4.2.1 Access  
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Boyne & James (1980)220 described the lateral access to MS using a modified Caldwell-
Luc procedure. In 1986, Tatum221 reported on his early results with a crestal approach 
to the maxillary sinus and simultaneous placement of implants. The need for the lateral 
approach can be dictated by the residual bone height. Less than 5 mm of residual bone 
height is commonly stated as the indication for the lateral access sinus grafting 
procedure29; however, this figure is rather arbitrary237. The lateral SFE is advocated for 
severely resorbed posterior maxillary sites to place big volume grafts in a controlled 
manner, combined whether with delayed or immediate implant placement29. While the 
lateral approach provides vision and better control of the surgical site, it is also more 
invasive.  
1.4.2.2 Maintaining augmented space 
A variety of biomaterials (reviewed in section 1.3 of this chapter) have been developed 
for SFE. In general, the biomaterials in SFE serve as wound stabilizers and space 
maintainers that prevent SM collapse. If the augmented space is maintained for 
sufficient time by means other than placing autologous bone or its substitutes, the de-
novo formation of bone is thought to occur238. In a case report, Lundgren et al. (2004)117 
claimed that the creation of space between the antral bone and the Schneiderian 
membrane could result in new bone formation around implants in the maxillary sinus, 
even without the use of bone graft materials. These findings were confirmed 
histologically in an experimental animal model114. Multiple reports were published 
concerning radiographic and histologic evidence of no-graft SFE in animals and 
humans239.  
However, maintaining augmented space without grafting can be a challenging task. In 
an experimental study in primates, a resorbable polylactide device was used, but the 
new extra-skeletal bone failed to form, probably due to the quicker-than-needed 
resorption of polylactide240. In another primate study, a titanium space-maintainer was 
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employed, and new bone formation was observed. However, the augmented tissue 
was greatly reduced in volume between 3 and 6 months and, in most cases, the space-
maintainers perforated SM113. A recent systematic review241 included five randomized 
clinical trials and one cohort study; it concluded that non-grafted SFE is a viable cost-
reducing technique, resulting in a high implant success rate. The authors stressed the 
need for studies with a longer follow-up. 
1.4.2.3 Piezo-electric devices 
Traditionally, to gain access through the sinus walls, burs or trephines have been used. 
However, concerns were raised about heat damage to the bone while drilling and SM 
perforations242, 243. Piezo-electric devices were introduced to provide a solution to these 
concerns244. In these devices, a high-frequency alternating electrical current is 
transmitted to the piezo crystals, causing their expansion and contraction. These 
mechanical oscillations are transferred to the working tip of the piezo-electric device, 
which is able to disrupt and fragment solid bone tissue but leaves soft tissues intact245. 
The main disadvantage of piezo-electric devices is operation time, which can be 
increased as much as five-fold compared to the rotary instruments246. 
Trisi et al. (2011)247 investigated early osseointegration of implants placed in the 
osteotomies, which had been prepared by piezo-electric and rotary devices using a 
sheep mandible model. The piezo-electric group demonstrated less peri-implant bone 
resorption. Similar findings were reported in mini-pigs248. 
Quality data concerning use of piezo-electric devices for SFE in humans is scarce. A 
recent systematic review included only four studies, three of them with a high risk of 
bias249. The authors failed to find a statistically significant difference between rotary 
and piezo-electric devices for prevention of SM perforations but confirmed the 
prolonged operation time with piezo-electric devices. Also, they discuss the 
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importance of operator experience for prevention of SM perforation with any of the 
devices. 
1.4.2.4 Use of membranes  
When using lateral access for sinus grafting, the access window can be covered with 
the barrier membrane. The barrier is thought to prevent the migration of connective 
tissue and epithelial cells according to the principles of guided bone regeneration250. 
Histomorphometric evidence of enhanced bone formation, following membrane 
placement over the lateral window, is available. In a randomized controlled clinical 
trial with a split‐mouth design214, bilateral sinus grafts were performed for twelve 
patients with or without covering the lateral window using a non-resorbable 
membrane. At re-entry after 12 months, biopsies were taken. The mean new bone 
fraction was 25.5% with and 11.9% without a covering barrier. Similar results were 
obtained in a controlled clinical trial251 measuring bone formation in 113 sinuses. The 
mean new bone fraction was 27.6% when a membrane was used, compared to 16% 
without. However, a recent systematic review of histomorphometric outcomes252 failed 
to find any statistically significant difference in new bone formation when the 
membrane was placed over the surgical window. 
Clinical outcomes of placing barriers over the access window were also investigated. 
The earlier systematic reviews74, 77 supported the use of barriers over the access window 
and reported higher implant success rate in membrane-covered sites. However, a more 
recent review done by the Cochrane Collaboration253 included only one trial at a high 
risk of bias with 106 patients, which investigated implants in covered and uncovered 
sites. After one year of loading, no statistically significant difference was reported for 
implant failure.  
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In this systematic review, Esposito et al. (2014)253 compared the impact of different 
protocols of SFE on implant failure: 
1. Lateral versus trans-crestal access to the sinus (one trial). 
2. Rotary instruments versus piezo-surgery to open lateral sinus window (one 
trial). 
3. One-stage (implant placement at the time of SFE) versus two-stage (delayed 
implant placement) lateral sinus lift (one trial). 
4. Using or not using the barrier membrane to seal the lateral window (one trial). 
5. Different bone substitutes and autologous bone grafts (two trials). 
6. Rotary versus hand malleting for the trans-crestal approach (two trials). 
No statistical difference in terms of implant survival was observed for any of the tested 
protocols. The number of included studies and the quality of evidence was relatively 
low. 
1.4.3 Alternatives to augmentation 
When the bone height is inadequate to support a long implant, a short implant can be 
used instead (just what distinguishes a “long” or “short” implant is somewhat 
arbitrary). Earlier studies have reported reduced success rates for shorter implants254; 
thus, longer, 13-18 mm implants were recommended in clinical practice. To be 
consistent with the current literature, we will address implants less than 10 mm in 
length as short implants. More recent reports and several systematic reviews 
demonstrate that implant survival and success seems to be similar for both short and 
long implant groups255-257. Despite having similar failure rates, peak failure incidence 
for shorter, <10 mm implants was reported to be 2.5 years earlier than longer 
implants256. None of the prosthetic factors influenced short implant failure258, 259: crown-
to-implant ratio, splinting, occlusal table, cantilever length, implant system, opposing 
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dentition, and bruxism. Tawil et al. (2006)259 followed implants shorter than 10 mm for 
53 months on average and found no statistically significant correlation between peri-
implant bone loss and the crown-to-implant ratio or cantilever length. 
However, short implants placed in posterior maxilla demonstrated lower survival 
rates compared to long implants4, 260, 261. The possible reasons for implant failure in 
posterior maxilla were discussed in section 1.1 of this chapter. In brief, lack of primary 
stability, reduced bone quality, increased mastication forces and unfavourable stress 
distribution in this anatomical site are thought to impact the survival rates of the 
implants. Also, in cases of the extremely resorbed posterior maxilla, even 4-6 mm 
implants may not have the required bone support, indicating the need for SFE prior to 
implant placement. 
Other alternatives to SFE were reported in the literature: zygomatic implants262, all-on-
four rehabilitations263, and angulated abutments264, to name a few. These alternative 
treatments may provide viable options in certain clinical situations. However, they are 
too case-specific and dependent on operator technique and experience to fully replace 
SFE in clinical practice.  
1.4.4 Conclusions 
SFE procedures for implant placement are considered predictable and safe. A variety 
of modifications of the original surgical protocols have been introduced. Maintaining 
the augmented space is paramount for the extra-skeletal bone formation to occur. This 
may be achieved by grafting the sinus with autologous bone or bone substitute. Other 
methods of maintaining space have also been shown to be successful and cost-effective; 
however, they can be less predictable and more operator-demanding. The use of 
piezoelectric devices to prevent heat damage to the bone and SM perforation, and use 
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of barrier membranes to cover the access window, have been advocated and supported 
by some authors and systematic reviews. 
Alternatives to implant placement in the grafted sinus have also been reported in the 




1.5 Animal models 
Due to ethical considerations, newly developed materials for implantation should be 
tested in non-human models prior to clinical tests in humans. While the in-vitro testing 
may provide valuable information about cell-material interaction and possible toxicity 
in an easily standardized and controlled medium (and prevent the non-suitable 
materials from being needlessly tested on animals), the cultured cells cannot represent 
the response of an entire tissue or the organism itself. The animals can provide the 
complex environments which are needed to assess the behaviour of implanted 
biomaterials fully. 
Several animal models were developed in orthopaedic and dental implant research. 
The key factor to consider when choosing an animal model is the level of physiological 
similarity of the experimental site in the animal to the corresponding anatomical site 
in humans.  
Pearce et al. (2007)265 summarised the biologic similarity of animal bone to the human 
bone for dental implantology; the summary is reproduced in Table 1-2. The authors 
have compared the animal bone tissue to that of humans in terms of macrostructure 
(dimensions, weight, stiffness, resistance to fracture), microstructure (trabecular 
density, porosity, lamellar and Haversian structure), bone composition (chemical 
composition, bone ash density) and bone remodelling (mechanics of bone repair and 
remodelling, rate of regeneration and remodelling)265.  Other considerations in 
choosing the model may include the animal’s ability to withstand and recover from 
surgery, costs of handling and housing, the availability of the animals, and 




Table 1-2 Similarity between human and animal bone characteristics 
 Dog Sheep/Goat Pig Rabbit 
Macrostructure ++ +++ ++ + 
Microstructure ++ + ++ + 
Bone composition +++ ++ +++ ++ 
Bone remodeling ++ ++ +++ + 
Adapted from Pearce et al. (2007) 265  
Similarity to human bone: + least similar, ++ moderately similar, +++ most similar. 
1.5.1 Small animals 
Small animals, such as rabbits and rats, are extensively used in orthopaedic and dental 
research. Despite the differences in bone biology (healing and remodelling are much 
slower in humans) and the need to adapt the implantable devices to the animal size, 
the small animals are relatively cheap, easy to handle and reach maturity earlier than 
the large ones265.  
Rats were not used as an SFE model due to them being too small. Rabbit SFE models, 
however, were reported119, 267, 268. Rabbits’ maxillary sinus anatomy bears enough 
similarity to that of humans269. Like humans, the air pressure through the ostium can 
lead to the collapse of the rabbit’s maxillary sinus membrane and affect the augmented 
bone structure270, which provides a viable physiologic model for SFE. 
1.5.2 Large animals 
Large animal models’ advantages are the ability to use ‘human-size’ implantable 
devices, and the bone healing rate, which is closer to that of humans. For SFE 
modelling, the size of the sinus is important, therefore, in this process, large animals 






Dogs have been extensively used in dental implantology research. A study by Aerssens 
et al. (1998)271 examined the differences in bone composition, density and quality 
between various species (human, dog, sheep, pig, cow and chicken). The authors stated 
that the canine bone tissue had most similarity to the human one.  
Using dogs for SFE research, was, however, criticized by Haas et al. (1998)272. The 
authors stated that the dog model is not comparable to humans for the lack of 
Schneiderian membrane and lack of pneumatization. In contrast, Rosen and Sarnat 
(1955)14 have demonstrated sinus pneumatization in dogs after tooth extraction on one 
side. Perhaps the most important consideration is the dog being a companion animal, 
which raises additional ethical questions and reduces the willingness of ethical 
committees to approve dog-based experiments266. 
1.5.2.2 Pigs and minipigs 
The anatomy of pig sinus is suitable for grafting and similar in size to human sinus156, 
273. Commercially available breeds of pigs grow to excessively large sizes, and their 
handling may be difficult and even dangerous. The development of mini-pigs 
overcame this problem to some extent and multiple SFE studies in porcine models are 
using mini-pigs116, 156, 161, 274. The intra-oral approach to the antral wall in a porcine model 
requires a wide surgical extension of the vestibule230. Also, unlike the human 
edentulous maxilla, the antral wall in pigs is relatively thick, dense and difficult to 
trephine230. 
1.5.2.3 Sheep and goats 
Sheep and goats are analogous animals for the purpose of SFE research265. Their bone 
shows considerable resemblance to human bone in terms of macrostructure265, 275 and 
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chemical composition271. Both sheep and goats were used in SFE research121, 126, 276, 277. In 
New Zealand, the domestic sheep (Ovis aries) are commercially available in large 
numbers, their handling is easy, and the cost is relatively low. Being an industrially 
farmed animal, their use in scientific research tends to be more acceptable by society. 
Our institution accumulated considerable knowledge about the sheep model in 
implant278-280 and SFE281-283 research.  
After a post-mortem study, Brumund et al. (2004)284 stated that general nasal anatomy 
and the paranasal sinus anatomy in sheep are similar to humans in appearance and 
orientation. A different study230 demonstrated that the antral wall in sheep is thin 
enough to resemble the antral wall of the human posterior edentulous maxilla. Like in 
pigs, the intra-oral approach to the antral wall in sheep requires vestibular enlargement 
prior to the actual SFE procedure230. An alternative, extra-oral approach was developed 
by Haas et al. (1998)272.  
Table 1-3 Sheep vs human bone healing 






































When researching consolidation of grafting materials, the rate of healing and repair of 
the animal is to be taken into account. Bone defect repair was used by Duncan (2005)278 
to estimate the difference between human and sheep healing rate and found that sheep 
bone repairs approximately 30% faster (Table 1-3). 
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The trabecular bone of skeletally immature sheep is weaker, more elastic, has higher 
shock absorptive qualities, contains more collagen, is less dense and more porous than 
that of skeletally mature sheep285. Hence, for more coherent results it is important to 
choose animals of similar age for the study. 
1.5.2.4 Primates 
Nonhuman primates, though closest to humans from the point of view of bone biology, 
are rarely considered as models for bone repair because of their high cost, low 
availability, handling difficulty and ethical concerns286. 
While SFE research was reported in primates114, 287, 288, the number of studies is relatively 
low. The increasing resistance of the ethical committees to approve primate-based 
research throws into question future reproducibility of outcomes of the primate-based 
studies. 
1.5.3 Conclusions 
Animal testing is a necessary step in developing implanted materials for clinical use in 
humans. A variety of animal models have been developed for sinus floor elevation 
(SFE) research. When considering the degree of physiologic similarity to humans, 
together with the animal availability, cost, ease of handling and ethical concerns, sheep 
and goats seem to be well-suited for SFE research.  
There is a growing body of work using the ovine sinus model, in part by our institution. 
The results from the ovine sinus model should be both relevant to humans and easily 
reproducible by other groups.   
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1.6 Analytical techniques for graft consolidation 
Graft consolidation in clinical practice is usually assessed either by direct observation 
at re-entry or indirectly by radiography. In research, the histologic analysis provides 
the basis of knowledge about graft consolidation, osseous healing, foreign body 
reactions and graft decomposition on tissue and cellular levels. The histomorphometric 
analysis is done by sectioning the histologic image into portions occupied by different 
tissues. For SFE, the newly formed bone (NB), the residual graft (RG), and the 
connective tissue (CT) are commonly measured210, 289. 
In humans, the histologic analysis is restricted to partial biopsies at the time of implant 
placement185, 202, 290. A meta-analysis by Corbella et al. (2016)289 included 84 human 
studies reporting histomorphometric outcomes of SFE with different grafting 
materials. These analyses were mainly carried out to evaluate the material resorption 
and the presence of new bone tissue using haematoxylin & eosin or toluidine blue 
staining, alone or in combination with tri-chromic staining, the latter to reveal collagen 
fibres. 
Animal studies routinely report histologic and histomorphometric outcomes of SFE268, 
273, 276. In animals, whole grafted areas can be sectioned and analyzed at multiple time-
points. 
1.6.1 Demineralized sections 
Direct histologic preparation of osseous tissues is impossible as the specimens are 
destroyed during sectioning. While prone to artefacts and tears291, demineralization 
allows for specimen preparation from the ossified tissues. The specimens are 
demineralized (usually using ethylenediaminetetraacetic acid (EDTA)), embedded, 
typically, in paraffin and cut into thin, 4 - 7 μm sections. The basic histological staining 
with haematoxylin and eosin (H&E) allows for visualization of the cells and non-
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mineralized extracellular structures291. Staining with immunohistochemical markers is 
used to identify specific cells types or cellular activity. 
Paraffin-embedded demineralized sections were used in both animal116, 119, 270 and 
human SFE studies292, 293. 
1.6.2 Undemineralized sections 
Mineralized bone is very stiff; it yields histological sections with less destruction and 
chatter when the surrounding embedding material is also stiff. Since the 1940s, 
histological examination of undemineralized bone tissue has been facilitated by 
embedding the bone tissue in one of several plastic formulations294. The resin block 
with embedded specimens are sectioned, and the sections are then ground to the 
microscope-suitable thickness (5-100 μm). Unlike the demineralized sections, un-
demineralized specimens allow for comparison between more mineralized, mature 
bone and less mineralized, woven or laminar bone. Distinguishing between osseous 
structures is important for histomorphometric analysis, where areas occupied by the 
newly formed bone, the grafting material and the connective tissue are determined. 
Multiple groups use undemineralized sections in human204, 295, 296 and animal-based7, 297, 
298 SFE research, ensuring the relevance and reproducibility of results using this 
method. 
1.6.3 Measurements 
Selection of the region of interest (ROI) for performing the histomorphometric analysis 
is a debatable subject, and no consensus has been reached between the various research 
groups. Some authors185, 186, 298 include the whole augmented site in the analyzed ROI. 
Others attempt to analyze the gradient of graft consolidation by dividing the ROI into 
zones – from the area closer to the floor or wall of the sinus, towards the elevated SM.  
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Busenlechner et al. (2009)155 defined  three ROIs: R1 – bridging distance to the sinus 
walls; R2 – intermediate distance; R3 – distant bone formation. 
De Lange et al. (2014)204 specified three square areas of interest, each of 625 µm2 starting 
at 500 µm distance from the sinus floor. 
Alayan et al. (2015)7 divided the specimen into three equal-area zones by proximity to 
the sinus wall.  
While the consolidation gradient of the graft was demonstrated in these studies, the 
reproducibility and clinical relevance of the gradient is questionable. In my study, the 
whole augmented site was analyzed for histomorphometric parameters. 
1.6.4 Conclusions 
Histologic and histomorphometric analysis remain the mainstay of animal-based 
research of sinus floor elevation. Undemineralized sections are widely used and are a 
reproducible method for producing histomorphometric outcomes. Although the 
choice of the region of interest varies between groups, attempts should always be made 




1.7 Aims of study 
The aim of this study was to prove non-inferiority of three novel and commercially 
available bone substitutes to a commonly used xenograft (control) for sinus floor 
elevation in, a well-known sheep maxillary grafting model using an extra-oral 
approach. The experimental materials (the alloplast and the xenograft) are not 
principally different from the materials that are already in clinical use. However, the 
intra-surgical handling of the experimental materials is thought to be superior. Also, 
the equine source of two of the experimental materials may be more readily accepted 
by some religious patients.  
1.7.1  Research question 
There is no data available concerning the outcomes of sinus grafting with the exact 
formulation of two of the tested products. A third product (IBI SmartBone®) was used 
in a recent case series in humans and demonstrated favourable histomorphometric 
outcomes, being replaced by viable bone. The small sample size of this report did not 
allow us to draw a quantitative hypothesis.  
In my study, two hypotheses were tested: 
1. The histologic and histomorphometric outcomes of sinus floor elevation in 
sheep using three novel bone substitute products (equine collagen cone, equine 
collagen cone filled with biphasic calcium phosphate particles, and 
deproteinized bovine bone particles coated with polylactic acid and poly ε -
caprolactone copolymer) are not statistically different to the commonly-used 
xenograft (Bio-Oss®) 
2. The handling properties of the experimental bone substitute products are 
superior to those of the commonly-used xenograft (Bio-Oss®) 
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Chapter 2. Materials and Methods 
The study population, the intervention, and the measurements will be described in this 
section. This study followed the ARRIVE guidelines299 for the reporting of in vivo 
experiments. This study was performed in accordance with the New Zealand Animal 
Welfare Act (1999). The Otago Animal Ethics Committee approved the study under 
protocol number AEC 78-14. The animals in this study were also used by another 
group for alveolar ridge preservation research. The results of this study were reported 
elsewhere300. 
2.1 Experimental animals 
Eleven female cross-bred ewes from the Hercus Taeri Research Unit Breeding Station 
were selected for the study according to the following criteria: 
2.1.1 Inclusion criteria 
1. Age 3-4 years 
2. Weight 70 kg or more. Underweight animals are more prone to surgery 
complications and have slower recovery overall. 
3. Complete dentition. Missing teeth are thought to be a sign of broken-mouth 
periodontitis301.  
2.1.2 Exclusion criteria 
1. Infectious pododermatitis (footrot). This condition requires antibiotic therapy. 
Otherwise it can cause lameness, loss of weight, and poor recovery after 
surgical procedures302. 




2.1.3 Pre-intervention management 
All included animals were tagged, treated for parasites, immunized and relocated to a 
secure pasture before the intervention. 
They were held in a separate paddock for 48-72 hours prior to the surgery and were 
not allowed oral intake of food and fluids for 24 hours prior to general anaesthesia.  
2.1.4 Statistics and power 
A number of studies using xenografts, allografts and combination grafts for SFE in 
sheep were published using various sample sizes121, 126, 276, 297, 298. In studies where the 
sample size was larger than ten animals, the authors discovered statistically significant 
histomorphometric outcomes. An additional consideration comes from our 
collaboration with another group that used the same animals for alveolar ridge 
preservation research300. The previous study of alveolar ridge preservation in sheep 
sampled eight animals and did not reach statistical significance303. By increasing the 




2.2 Grafting materials 
2.2.1 IBI SmartBone® (Industrie Biomediche Insubri SA CH-6805 
Mezzovico-Vira, Ticino, Switzerland) 
SmartBone® (SB) is a commercially available novel xenograft of bovine origin. While 
the bovine bone xenograft is not an innovation on its own, SmartBone® bovine 
xenograft matrix is coated with degradable synthetic poly (L-lactide-co-ε-
caprolactone) (PLA-PCL) and gelatin. The manufacturer states this coating should 
improve the mechanical properties of otherwise brittle xenograft and provide 
better cell adhesion. The addition of gelatine increases the graft’s wettability by blood. 
Unlike particulate grafting materials, the PLA-PCL coating allows SmartBone® to 
withstand stress, such as shaping it with files or pliers for better adaptation, drilling 
holes into the material, or securing it with screws to the recipient site (Figure 2-1). The 
material is porous, with 27% of its volume occupied by air, to allow for quicker tissue 
ingrowth and vascularization304. SB used in this study comes in a shape of a porous 
rigid cube 10 x 10 x 10 mm.  
 
Figure 2-1 SmartBone® (courtesy of IBI) 
A. The material is available in shaped rigid porous blocks 




2.2.2 PARASORB Cone® (Resorba Wundversorgung GmbH, 
Nürnberg, Germany)  
PARASORB Cone® (CN) is a commercially available resorbable type Ⅰ collagen cone 
(Figure 2-2). One cone, diameter 1.2 cm, height 1.6 cm, contains 22.4 mg of equine 
collagen. The collagen fibrils are not cross-linked, they are reconstituted using a 
proprietary technology305.  The recommended use of this product is wound 
stabilization and haemostasis after tooth extractions. Off-label uses have also been 
reported, mainly as a scaffold and vehicle for biologic agents306, 307. 
2.2.3 PARASORB Cone Oss® (Resorba Wundversorgung GmbH, 
Nürnberg, Germany)   
Cone Oss® (CO) is a novel and not yet commercially available product consisting of 
an equine collagen cone (identical to CN) with suspended biphasic calcium phosphate 
(BCP) granules. The BCP used for this product is a combination of 60% hydroxyapatite 
(HA) and 40% beta-tricalcium phosphate (β-TCP). The β-TCP portion is thought to be 
resorbable while the HA should remain in the grafted site as a scaffold for long-term 
volume preservation308. This product concept resembles that of Bio-Oss Collagen®: a 
combination of osteoconductive mineralized graft in a collagen scaffold. The scaffold 
holds the graft particles together, allowing for easier handling and special orientation 
in the grafted site. It is soaked in blood and replaced by invading granular tissue and 
newly forming vasculature. Unlike Bio-Oss Collagen®, the CO graft particles are 
synthetic; their composition resembles the biphasic Straumann Bone Ceramic ® 
grafting material.  
The composition of CO is demonstrated in the cross-section in Figure 2-2 The collagen 
component is white, and the BCP phase is stained with methylene blue for 
demonstration purposes. The periphery and the apical portion of CO are mouldable to 
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allow better adaptation to various defect sizes. The collagen content also provides 
primary haemostasis. 
 
       
Figure 2-2 PARASORB Cone Oss® and Cone®  
Both materials have conical shape; Cone Oss® is essentially a Cone® filled with biphasic 
calcium phosphate (BCP) granules  




2.2.4 PARASORB Resodont® (Resorba Wundversorgung GmbH, 
Nürnberg, Germany) 
PARASORB Resodont® is a commercially available resorbable type Ⅰ  collagen 
membrane (Figure 2-3). The collagen is non-cross linked and manufactured by the 
complete reconstitution of equine collagen. Unlike porcine or bovine collagens, the 
equine origin does not give rise to religious concerns, such as in Muslim or Hindu 
populations. PARASORB Resodont® collagen membrane contains 2.8 mg native 
collagen fibrils per 1 cm². According to the manufacturer, unlike Geistlich Bio-Gide®, 




A new package of 22x25mm of PARASORB Resodont® was opened for each animal 
and trimmed to the size of the defect, prior to placement over sites grafted with CO. 
 
Figure 2-3. PARASORB Resodont®. Courtesy of RESORBA® 
 
2.2.5 Bio-Oss® (Geistlich Pharma AG, Wolhusen, Switzerland) 
Geistlich Bio-Oss® (BO) is a xenograft from bovine origin. BO is probably the most 
extensively studied bone substitute material in dentistry309, 310. Multiple groups use this 
material as a positive control to test novel products in humans and animals 161, 201, 203, 206, 
281.  
  





Commercially available 0.5 g packages of BO were used in the experiment (Figure 2-4). 
For every surgical site, a new package was opened, a standardized measured amount 
of BO was dispensed in a 0.8 ml Dappen dish, then mixed with the saline and used for 
grafting. 
2.2.6 Bio-Gide® (Geistlich Pharma AG, Wolhusen, Switzerland) 
The Bio-Gide® membrane is a resorbable collagen membrane of porcine origin. The 
membrane is produced without chemical additives or further cross-linking. Bio-Gide® 
has a bilayer structure with the smooth, cell-occlusive side, and the rough, cell-
permeable side which should be facing the graft.  Bio-Gide was used in a single layer 
over the sites grafted with BO. A new package of 25x25mm of Bio-Gide® was opened 




2.2.7 Allocation and randomization 
Each animal received all four treatment modalities: one positive control with BO and 
Bio-Gide®, and three test modalities with CN, CO and SB as described above. 
The sites for grafting in all animals were allocated prior to the intervention. To 
eliminate a possible bias from the consistent placement of specific grafting material in 
specific sites, the allocations were rotated for every subsequent animal as presented in 
the Table 2-1. 









412 CO† BO† SB† CN† 
413 CN BO CO SB 
414 SB CN BO CO 
415 CO SB CN BO 
416 SB‡ CO BO‡ CN 
417 CN BO CO SB 
418 SB CN BO CO 
419 CO SB CN BO 
420 BO CO SB CN 
421 CN BO CO SB 
409 SB CN BO CO 
CO – PARASORB Cone Oss®; BO – Geistlich Bio-Oss®; CN – PARASORB Cone®;  
SB – IBI SmartBone® 
† - The allocation for the first operated animal was arbitrarily chosen. We decided to use more 
organised allocation scheme for the subsequent animals. 




The study design is summarized in Figure 2-5 
 
Figure 2-5 Study design diagram 
  
Bilateral sinus surgery 
N=11




Did not recover 
from surgery, N=1 
55 
 
2.3 Surgical protocols 
2.3.1 Surgical grafting procedure 
All grafting procedures were performed in Invermay Agricultural Research facilities 
between 3rd and 13th of February 2015. 
2.3.1.1 General Anaesthesia 
We pre-medicated all experimental animals with antibiotics (trimethoprim, 
Amphoprim® injection 1ml/15kg, Virbac New Zealand Ltd., East Tamaki, Auckland) 
prior to the intervention. We induced the general anaesthesia by means of intravenous 
infusion of thiopentone 20mg/kg (Bomac Laboratories Ltd., Manukau City, Auckland). 
After placement of the sheep on a mobile operating table, an endotracheal tube was 
inserted via the oral route, an endotracheal balloon was inflated, and the tube was 
secured to prevent displacement. Anaesthesia was maintained with 1-2% halothane. 
We placed a gastric tube to decompress the stomach, and the gastric content was left 
to drain freely into a container placed beneath the surgical table. We used a pulse 
oximeter to monitor the vital signs of the experimental animal during the surgical 
procedure. 
2.3.1.2 Pain control 
Prior to intervention, we infiltrated the dedicated surgical site with local anaesthetic: 2 
X 2.2ml of mepivacaine 2%, with adrenaline concentration 1:100000 (Scandonest®, 
Septodont, Ivoclar Vivadent Ltd., Auckland New Zealand). This prolongs the action of 
local anaesthetic and helps to control bleeding during the surgery.  
After closing the surgical access wound with sutures, we administered 1 ml of 
Bupivacaine hydrochloride 0.5%, with adrenaline 1:200000 by local infiltration 




2.3.1.3 Surgical procedure 
After rotating the head of the animal onto the side, we shaved the wool over the 
surgical site, exposed the skin, then cleaned and disinfected the site with Betadine® 
solution (Alcon Laboratories, Inc. Rockville Pike, Bethesda, MD, USA). We used 
disposable sterile draping to cover the animal, except for the surgical site. 
We adopted the surgical approach from Haas et al. (1998)121. We accessed the antral 
wall extra-orally. First, a para-median oblique sagittal skin incision about 6 cm in 
length was done to the subdermal level inferior to the lower eyelid, using the 
electrosurgical unit (NeoMed™ 3000A ESU, Solid State Electrosurgery Unit, USA). 
 After that, by using a combination of sharp and blunt dissection with electrocautery 
to control the bleeding, we exposed the masseter muscle and then separated about 1 
cm of this muscle from its origin. Soft tissues were retracted. By gentle percussion on 
the antral wall, we verified the presence of the sinus space prior to outlining the 
osteotomy location with the trephine.  
We created two osteotomies on each side of the animal, meaning a total of four 
experimental sites per animal (Figure 2-6). A circular bone window was demarcated in 
the anterior part of the exposed maxilla, using a cup-shaped trephine 10 mm in 
diameter, with saline cooling, without perforating the full thickness of the bone. The 
central part of the window was finally separated with a piezo-surgical device – 
Mectron® Piezosurgery 2 ultrasonic unit (Henry Schein Shalfoon™, Auckland NZ) – 
using the OT5 round diamond-coated tip. 
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Figure 2-6 Surgical procedure 
A – Surgical sites location. B – Soft tissue dissection. C- Osteotomy preparation. D – Grafting 
materials in place (black arrow – Bio-Oss®, empty arrow – Cone Oss®). E – Bio-Gide® 
membrane to cover the Bio-Oss®. F – Primary closure of the soft tissues. 
 
The bone from the central portion of the osteotomy was detached from the 
Schneiderian membrane (SM), removed and discarded. The SM was elevated 
superiorly and distally using sinus membrane dissectors (Sinus Kit, Osstem™, Korea) 
and checked for perforations. We positioned the second osteotomy 8 mm posteriorly 
to the first one, and the Schneiderian membrane was also elevated and checked for 
perforations. If an SM perforation was identified, we used a barrier membrane to line 
the defect and prevent the grafting material from penetrating into the maxillary sinus 
according to the Loma-Linda pouch technique311. We used PARASORB Resodont® 
membrane, for the repair. Where sinus anatomy resulted in a limited available space 
due to a presence of septae or sinus hypoplasia, an alternative osteotomy was prepared 
in the same surgical site.  
C B A 
D E F 
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The pre-allocated material was placed under the elevated SM in the following manner: 
BO was mixed with saline prior to grafting. SB block was also mixed with saline and 
pounded in a Dappen dish to a particulated form, using a blunt hand instrument. CN 
and CO were transferred into the surgical site straight out of their sterile package. We 
took care not to deform the CN and CO.  The grafting materials were described in the 
previous chapter, and are summarized in Table 2-2  
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Table 2-2 Summary of grafting materials and membranes 









Resorbable equine collagen filled with 






Composite bone substitute made of 
deproteinized cancellous bovine bone 
coated with poly(L-lactide-co-ε-






Deproteinized bovine cancellous bone Geistlich Biopharma 
AG (Switzerland) 




Equine collagen resorbable membrane RESORBA Medical 
GmbH (Germany) 
 
We placed a barrier membrane (Table 2-3) over the access window so that all 
membrane edges were supported by at least 5 mm of a sound bone. The muscle and 
fascia layers were repositioned and sutured using resorbable 3/0 polyglycolic acid 
sutures (PGA Resorba®, catalogue number PA1117, RESORBA Medical GmbH, 
Nürnberg, Germany). The dermis was sutured with synthetic resorbable 




Table 2-3 Use of membranes in surgical sites 
Type of grafting material Membrane to cover the access window 
Bio-Oss ® Bio-Gide ® 
PARASORB Cone Oss ® PARASORB RESODONT® 
PARASORB Cone ® PARASORB RESODONT® 
SmartBone ® PARASORB RESODONT® 
 
2.3.1.4 Post-surgical management 
Halothane was stopped, and the animal was extubated and moved to a separate 
individual recovery area for a few hours under the monitoring of the veterinary 
technician. 
For three days following the surgery, the sheep were kept in a designated paddock, 
where they were monitored and received postoperative regimen. During this period 
each animal received: 
• Mouth-rinse once a day with 30ml of 0.2% w/v chlorhexidine gluconate 
solution (Savacol®, Colgate-Palmolive, NZ) 
• Subcutaneous injection of anti-inflammatory medications, 5ml carprofen 
(Rimadyl® injection 50mg/ml, Zoetis, Mt Eden, New Zealand) once a day 
• Subcutaneous injection of antibiotics (Trimethoprim 1ml/15kg) once a day. 
After three days of intensive postoperative care, the experimental animals were 
returned to pasture and were allowed to graze freely for the duration of the healing 
period. Sequential weight measurements were taken to confirm normal recovery. 
2.3.2 Sacrifice 
After 16 weeks of healing, the experimental animals were brought to the AgResearch 
Invermay facilities to be euthanised. 
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General anaesthesia was induced in the same way as during the initial surgical 
procedure. The animals were placed on an operating table in a Trendelenburg position 
(supine position, with the legs being higher than the head) with the neck overextended. 
The skin was incised along both sternocleidomastoid muscles, and the external carotid 
arteries were exposed by blunt dissection. Each artery was cannulated with a 14G 
catheter (Optiva TM, Smiths Medical, UK) and the catheters perfused with normal 




Figure 2-7 Exposure and cannulation of external carotid arteries  
A – initial incision; B – external carotid artery exposed; C – external carotid artery ligated; D 





Both catheters were secured with silk sutures to prevent their displacement. The 
external carotid arteries were ligated around the catheters to prevent the back-flow of 
the perfusing solution (Figure 2-7).  
After the catheterization was finished, each catheter was perfused with 1 L of normal 
saline (0.9% Sodium chloride, Baxter Healthcare Ply Ltd., NSW Australia) and 1.5 ml 
of 5000 IU heparin. After heparin perfusion, the animals were killed by an overdose of 
halothane for 2 minutes. The animals were then extubated, the carotid arteries were 
perfused with 1 L chilled formalin fixative per side, using 10% neutral buffered 
formalin (NBF) (BioLab Ltd., New Zealand). Both jugular veins were severed with a 
scalpel blade, and the heparinized blood was allowed to drain into a container on the 
floor.  
Once the operated sites were identified, maxillary sinus specimens were retrieved by 
en-bloc resections, rinsed with water, and placed into individual plastic containers. The 




2.4 Histologic sections preparation 
2.4.1 Trimming 
The anatomical orientation of the specimens was marked by inserting a silk suture in 
the anteroinferior position. The blocks were trimmed to a roughly rectangular shape 
and fitted into the perforated plastic cassettes 5 x 10 x 1.5 cm.  
 
Figure 2-8 Trimming and labelling of specimens 
A – Untrimmed specimen. (green dashed line – trimming outline; red arrow – silk suture 
indicating the anteroinferior corner of the trimmed specimen) 
B – The labelled specimen cassette with a pencil-marked paper label 
C – Trimmed specimen (red arrow – silk suture indicating the anteroinferior corner of the 
trimmed specimen)  






These cassettes were chemically stable and non-dissolvable in any of the solutions 
which were used during processing. They also served as label holders for specimens 
during processing. The cassettes were labelled with pencil writing on the outside 
(Figure 2-8).  
2.4.2 Resin embedding  
In order to perform non-demineralized histology, the tissues must be resin-embedded. 
The protocol for resin-embedding was initially described by Donath and Breuner312. It 
was further modified and refined by Duncan278. A recent project by our institution303 
followed this modified version, which was fully adopted for this study, and is attached 
as Appendix II. The labelled cassettes, each containing one specimen, were placed in a 
covered glass container under a fume hood. The tissues were dehydrated, cleaned, and 
embedded using the following steps: 
1. 20 % ethanol-water solution. The ethanol solution was changed after 2 days 
and then after 2 more days changed for 40% ethanol 
2. 40% ethanol-water solution for 2 days  
3. 75% ethanol-water solution for 2 days 
4. 95% ethanol for 6 days; the solution was replaced after 2 and 4 days 
5. 100% isopropanol for 6 days on an oscillating platform; the solution was 
replaced after 2 and 4 days  
6. Xylene (Ajax Finechem Pty Ltd, New Zealand) for 6 days on an oscillating 
platform; the solution was replaced after 2 and 4 days 
7. Washed with methyl meta-acrylate (MMA) monomer (Sigma Aldrich, USA), 
then put in activated MMA II solution (four parts MMA monomer, one part 




The cassettes with the specimens were washed again with MMA I monomer, after 
which the specimens were retrieved and placed into hermetically closing individual 
jars with a pre-set MMA-III (4 parts MMA monomer, 1part dibutyl phthalate and 1% 
benzoyl peroxide) base. These jars were filled with MMA-III to a depth of 8-10mm one 
week prior to the embedding process, to allow the MMA-III base to set. The paper label 
was transferred from the cassette to the jar, together with each specimen.  
The jars with the specimens were then fully filled with MMA-III solution. They were 
left to set in a cold-water bath and covered from light to slow down the exothermic 
polymerization reaction. If too fast, the polymerization may produce gas bubbles 
which may damage the specimen. 
   
 
Figure 2-9 Sectioning and staining of the specimens 
A – MMA-embedded specimen retrieved from the glass jar. B – specimen trimmed to a shape. 
C – orientation radiograph indicating two surgical sites (white arrows). D – slicing of the 
specimen into coronal sections using a precision microtome with a diamond wheel. E – the sliced 
coronal section is mounted onto a white opaque acrylic slide using cyanoacrylate glue. F – 







When the setting process was completed, the glass jars were broken to retrieve the 
acrylic resin blocks containing the tissue specimens (Figure 2-9). To simplify the slicing 
of the specimens, these blocks were trimmed down and polished to a rectangular shape 
with at least 2-3 mm of acrylic resin surrounding the embedded specimen. The 
trimmed blocks were marked with the specimen’s identification code, using a 
permanent marker. 
2.4.3 Slide preparation 
The radiograph of all the trimmed acrylic blocks was done to outline the area of interest 
for sectioning (see Appendix Ⅴ). The sectioning of the acrylic resin blocks (Figure 2-9) 
was done using Struers Accutom precision table-top microtome (Ballerup, Denmark) 
fitted with a diamond cutting wheel (MOD 13 127x0.4x12.7mm): Sequential sections 
700 µm wide were sliced; each section was mounted onto a white opaque acrylic slide 
using cyanoacrylate glue (MDS Adhesive QX-4, MDS Products Inc, Laguna Hills, CA, 
USA); the slides were then engraved with the specimen identifier using a straight 
dental hand-piece with a round bur. 
Between six and twelve coronal sections were cut from each specimen, depending on 
graft area anteroposterior width. Two coronal sections representing the central area of 
the grafted site were chosen for further processing.  
The selected sections were ground and polished from an initial 700 µm to microscope-
suited 80-100 µm using a Tegra-Pol rotary grinding machine (Struers, Ballerup, 
Denmark) and Silicon Carbide Paper (grit size #180 to #4000). The width of the sections 
was verified with a digital micrometre (Digital Indicator, Mitutoyo, Japan). 
2.4.4 Staining 
The mounted slides were immersed in 20% ethanol in the ultrasonic bath for five 
minutes to remove the debris and clean the surface.  The specimens were immersed in 
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1% formic acid in an ultrasonic bath for five minutes to allow for the stain penetration 
into mineralized tissues. The sections were then stained with a mixture of one-part 
MacNeal’s tetrachrome (methylene blue, azure II and methyl violet) and two-parts 
toluidine blue. MacNeal’s tetrachrome stain was originally developed to stain blood 
films313; it is classified as a neutral dye in which one of the components is acid and 
colours cytoplasm, the other is basic and colours nuclei, cartilage, mast cells, and acid 
mucins314. The modification of MacNeal’s stain with toluidine blue was described by 
Schenk in 1984315. The resulting stain colours the calcified bone and its components in 
shades from dark to light blue316. 
The staining protocol is described in further detail in Appendix III. The stained slides 




2.5 Histomorphometric analysis 
2.5.1 Imaging of histologic sections 
For histological analysis, high-resolution images were obtained using a light 
microscope (Olympus AX70, Olympus Optical Co. Ltd, Japan) and an imaging system 
(Micropublisher 5.0 RTV, Qimaging) at 10x magnification. Only a small portion of a 
full section is visible at this magnification; therefore, to obtain a complete scan of a 
section, a montaging technique was employed.  
Each section was scanned as a series of 20-80 images (depending on the size of the 
section) with a 10% overlap between the adjacent areas, using the Volocity 5.2.0 
(Improvision, MA, USA) montaging software. The image series was then stitched 
together into a single panoramic scan in Autopano Pro 2.5.2 (Kolor, USA), which 
automatically detects the matching points in the overlapping areas of the individual 
images. 
2.5.2 Histomorphometric analysis 
2.5.2.1 Region of interest 
The present study aimed to investigate the graft consolidation and a new bone 
formation in the augmented sinus. Therefore, the area between the sinus wall to the 
Schneiderian membrane was included in the region of interest (ROI) for analysis. For 
reproducibility of results, the following guidelines were implemented when outlining 
ROI for each specimen: 
1. A straight-line tangent to medial margins of repairing sinus walls was drawn. 
2. Two perpendicular lines tangent to the most distal hard tissue formations 
(graft or new bone) in the augmented area were marked. 
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3. A third line following the Schneiderian membrane connected the previously 
charted perpendicular lines. 
A representative slide with ROI is shown in Figure 2-10 
2.5.2.2 Histomorphometry 
The percentage of area within the ROI occupied by hard tissue was determined for 
each slide. McNeal’s tetrachrome stains the newly forming bone with greater intensity 
than the mature bone due to a higher glycosaminoglycan content in the newly forming 
bone. The differences in staining were used to digitally section images into areas 
occupied by graft, new bone and connective tissue. 
The image was sectioned into the graft, new bone and connective tissue sections 
(Figure 2-10) using a combination of: 
1. Automatic selection with colour threshold plugin (version 1.16 by Gabriel 
Landini, visit http://www.mecourse.com/landinig/software/software.html 
for details) of image analysis computer software, ImageJ (version 1.51n, 
National Institute of Health, USA), and  
2. The tracing tool of ImageJ software.  
The colour threshold plugin automatically selects all pixels specified by their colour. By 
manually adjusting the colour thresholds the graft and the new bone were selected 
separately. Due to variability in staining of the specimens and difference in the thickness 
of various parts of histologic slides it was not possible to fully rely on this automatic 
selection. The integrated tracing tool of ImageJ was used to add areas missed by automatic 
thresholding manually. This tool selects adjacent pixels within a certain predetermined 
range in colour. Connective tissue area was calculated by subtracting the graft and the 






Figure 2-10 Histomorphometric analysis 
A – the overview of the specimen with ROI outlined by red lines. B – magnified view of the 









2.5.3 Statistical analysis 
Two sections per surgical site were chosen to reduce a possible bias of having a mal-
positioned section. The average between the two sections was used for statistical 
analysis as the representative value for the respective grafted site. 
Mean values and standard deviations were calculated for all outcome variables. Non-
normal distribution was observed within groups, and the Wilcoxon signed rank test 
was planned to compare between groups. Differences were considered statistically 
significant when two-sided p was <0.05. The statistical analysis was performed with 
IBM® SPSS® software (version 23, International Business Machines Corp., Armonk, 




Chapter 3. Results 
3.1 Handling properties of grafting materials 
3.1.1 PARASORB Cone® 
Cone® (CN) can be easily removed from its packaging using tweezers. The material is 
spongy with high plasticity. It can easily be moulded into the desired shape and 
inserted into the dedicated surgical site. CN should be handled with dry gloves and 
instruments, as premature contact with blood will cause it to lose rigidity, thus making 
the insertion into the dedicated site more challenging.  
Compared to particulate grafts, the sub-membrane space created by CN is more 
defined by its conical shape. While it was easier to insert CN than BO, the operator had 
only limited control of the augmentation. 
3.1.2 PARASORB Cone Oss® 
PARASORB ConeOss® (CO) is essentially CN with alloplastic filler. The handling 
properties of CO was similar to those of CN.  
3.1.3 SmartBone® 
SmartBone ® (SB) used in the study came in the shape of a porous cube 10 x 10 x 10 
mm. It was easily retrieved from its packaging and manipulated. The material was 
porous but rigid. By grinding or cutting it could be adapted to a desired shape, 
however, it was impossible to pre-shape the cube to fit the sinus space due to the 
complex and unclear morphology of the recipient site. Therefore, the cube was soaked 




3.1.4 PARASORB RESODONT® membrane vs Bio-Gide® 
PARASORB RESODONT® is made of reconstituted equine type I collagen, whereas 
Bio-Gide® is composed of porcine type I collagen. Bio-Gide® membranes have two 
distinct surfaces: cell occlusive and cell permeable, which determines the correct 
placement - the rough, cell permeable surface is placed towards the graft. PARASORB 
RESODONT® has two identical surfaces, and applying a specific surface towards the 
bone is irrelevant. Compared to Bio-Gide ®, RESODONT® was more rigid and less 
adhesive to the bone, soft tissues, and itself, and therefore it was easier to handle under 




3.2 Post-operative healing 
The first animal that received the surgical intervention (number 412) failed to recover 
from the procedure. Despite recovering from general anaesthesia, it could not get up 
on its feet, feed or drink. It was assessed by the veterinarian and diagnosed with 
gastrointestinal complications due to a protracted surgery (about 6 hours). This animal 
was euthanized to prevent further suffering,. The grafted sites from the euthanized 
animal were excluded from the analysis, thus reducing the study sample to a total of 
10 animals. 
We shortened the time on the operating table for all subsequent animals. These animals 
recovered from the procedure with no complications. They were medicated and closely 
monitored before their release to pasture. All surgical sites healed uneventfully for 16 
weeks following the grafting procedure. The soft tissue healing was complete for all 




3.3 Descriptive histology 
3.3.1 Dermis and mucosa 
The healing of soft tissues was similar for all the grafting materials and experimental 
sites.  
3.3.1.1 Epidermis 
The layers of epidermis, dermis, muscle and fascia covering the antral wall were 
macroscopically intact. The cells and the extra-cellular matrix of the dermis were only 
lightly stained with McNeal’s tetrachrome solution. Therefore more in-depth 
descriptive analysis was not performed.  
3.3.1.2 Mucosa and submucosa 
The mucosal lining of the sinus wall, the Schneiderian membrane, presented as a single 
layer of pseudostratified columnar ciliated epithelium with multiple goblet cells. In 
proximity to the basal membrane, the submucosa was highly vascular. The vascularity 
was gradually diminished towards the deeper layers of lamina propria. Multiple 
mucinous glands in the immediate submucosa were well-stained and easily identified 





Figure 3-1 Schneiderian membrane and submucosa (CO site, specimen 409) 
A. Overview of the specimen. Red rectangle outlining the position of B 
B. Mucosa and submucosa (x4 magnification). b – new bone; g – graft; black arrows – 
Schneiderian membrane; empty arrowheads – goblet cells; yellow arrowheads– 
mucous glands; red arrows - capillaries 
The epithelial lining of the sinus was uninterrupted in all specimens, but there was one 
CO site (from the animal 414) where the membrane appeared to be disrupted, and the 
particles of graft were seen outside the boundaries of SM. During the grafting surgery, 
no perforations were detected at that site.  
Four SM perforations less than 5 mm were detected during the surgery in two animals. 
They were repaired as described in section 2.3.1.3 using barrier membrane (Table 3-1). 
We discovered that the grafting material disappeared completely from three of these 














Table 3-1 Schneiderian membrane perforations and outcomes 
Sheep Site Materials for 
repair 
Histologic outcome 
413 Bio-Oss® RESODONT® Successful augmentation, irregular SM.  
417 Bio-Oss® RESODONT® Failed augmentation 
417 Cone Oss® RESODONT® Failed augmentation 
417 SmartBone® RESODONT® Failed augmentation 
 
In several specimens, the epithelium lining appears to be irregular, containing multiple 
invaginations and evaginations. These specimens also presented with higher 
vascularity, and denser infiltrate of PMNs in the submucosa. The inflammation was 
not quantified as the McNeal’s tetrachrome staining is not optimal for immune cell 
identification and counting. 
3.3.2 Access window  
New bone formation between edges of the surgical wound in the bony walls of the 
sinus was evident in all specimens. For all treatment modalities, the newly formed 
bone (NB) was evident on both antral and facial sides of the original cortical bone 
plates. NB could be identified by darker staining, less regular structure, thin elongated 
trabeculae, and large marrow spaces. In 8 out of 10 BO grafted sites, 7 out of 10 CO 
sites, 8 out of 10 CN sites, and 2 out of 10 SB sites the surgically cut edges were 
impossible to locate with confidence due to remodelling and replacement by the new 





Figure 3-2 Healing of the surgical access window (BO grafted site, specimen 419) 
A. Overview. Red rectangles represent the positions of magnified B and C slides 
B. Exuberant healing and remodelling of the sinus wall. The original bone plate 
margins are difficult to identify (w – original sinus wall under remodelling; b – new 
bone; m – marrow spaces; g – xenograft particles; yellow arrow – artefact). 
C. Exuberant healing and remodelling of the sinus wall. The original bone plate 
margins are easy to identify (empty arrowheads - original sinus wall under 
remodelling; b – new bone; m – marrow spaces). 
The initial access size was outlined with a 9-mm round cup-shaped trephine bur; 
however, this wasn’t standardized between all sites due to the use of a piezosurgical 

















initial size of the defect was difficult to determine; the statistical inter-group analysis 
was not performed for initial defect size and healing (Table 3-2).  
Complete repair of the access window was evident in two specimens (1 BO, 1 CO). The 
mean residual gap was 3.7 mm; the differences between groups were not statistically 
significant (Table 3-2).  
Table 3-2 Repair of surgical defect in the wall of the sinus 
 BO (SD) CO (SD) CN (SD) SB (SD) 


























SD – standard deviation 
† - statistical analysis not performed  
‡ -in one sample a complete repair was observed, although the initial defect was not 
determined. 
* - p>0.05 between all groups 
3.3.3 Augmented sites 
In all specimens, the space between the mucosal lining and the bone wall of the sinus 
contained the submucosal connective tissue and the vasculature. In nine out of ten BO 
specimens and seven out of ten CO specimens an additional submucosal space was 
created by the grafting procedure, i.e. successful augmentation. This space contained 
the residual grafting material and the newly formed bone. In CN sites, no such 
additional space was found, and no residual grafting material was present. Among SB 
specimens, only one demonstrated additional submucosal space formation with 
residual grafting material and newly formed bone, i.e. successful augmentation. 
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Specific features were evident for sites augmented with CO, CN and SB. 
3.3.3.1 Bio-Oss® sites 
The sites grafted with BO presented as bell-shaped areas outlined by sinus membrane, 
under which the loosely packed residual graft particles were evident. In most cases, 
the residual Bio-Oss® particles were also found to be integrated within the newly 
formed bone of the sinus walls. In eight out of ten Bio-Oss ® specimens woven and 
lamellar bone was found in direct contact with residual graft particles within the 
defined region of interest (Figure 3-2, Figure 3-3).  
Upon closer examination at X10 magnification, multi-nuclear, osteoclast-like cells in 
formations resembling resorption lacunae were evident at the periphery and directly 







Figure 3-3 Bio-Oss® augmented site (specimen 414) 
A. Overview. Red rectangle represents the positions of magnified image in (B) 
B. Magnified X10 image of residual graft-new bone complex with resorption lacunae 













3.3.3.2 PARASORB Cone Oss® sites 
Similar to BO sites, the CO sites presented as bell-shaped areas outlined by sinus 
membrane. The residual graft particles in CO augmented sites were found to be tightly 
packed underneath SM, but the collagen matrix was completely resorbed and replaced 
by dense, cellular connective tissue. Newly formed bone appeared in five out of ten 
specimens of CO sites. Most of the new bone appeared in direct contact with the 
residual graft particles, both proximal and distant to the walls of the sinus. Due to the 
alloplastic particles’ innate surface irregularity, it was impossible to determine whether 






Figure 3-4 Cone Oss ® augmented site (specimen 419) 
C. Overview of the specimen. Red rectangle outlining the position of B 
D. Residual graft particles (x10 magnification, b – new bone; c – connective tissue; g – 

















3.3.3.3 SmartBone® sites 
Seven out of ten SmartBone® sites presented with no augmentation (Figure 3-5) Non-
resorbed grafting material was found in three out of ten sites grafted with SB. Two of 
those sites demonstrated no augmentation, i.e. no extra-skeletal bone was created by 
the grafting procedure. In one remaining specimen, the augmented area contained 
loose connective tissue with sparse islets of newly formed bone enveloping remaining 
particles of grafting material. The grafting material exhibited multiple resorption pits. 
These pits were in contact not only with the new bone but also with connective tissue, 
which suggests that the inflammatory process, rather than osteoclastic resorption, was 
responsible for the graft disappearance (Figure 3-6).  
 
 
Figure 3-5 SmartBone® augmented sites 
A. Specimen 416. Notice the irregular Schneiderian membrane (black arrow) with highly 
vascular sub-mucosa. No residual graft or newly formed bone is evident in ROI 








Figure 3-6 SmartBone ® residual grafting material (specimen 418) 
A. Overview. Red rectangle represents the positions of magnified B figure.  
B. Residual graft particles (x10 magnification b – new bone; c – connective tissue; g – 















3.3.3.4 PARASORB Cone® sites 
All sites presented with intact sinus epithelium and loose lamina propria, which was 
highly vascular near the epithelial basal membrane. In two out of ten sites, several 
isolated islets of woven bone were found within the submucosa. Three out of ten 
specimens demonstrated degenerate non-stained material in the region of interest 
(Figure 3-7). This material could be the residual non-resorbed grafting material, 






Figure 3-7 Cone® augmented sites 
A. Specimen 419. Collapsed Schneiderian membrane, failed augmentation. Degenerate 
residual grafted material is evident (empty arrowheads) 
B. Specimen 414. Collapsed Schneiderian membrane, failed augmentation. Degenerate 









3.3.4 Histological artefacts 
The methodology of slide preparation for histological staining involved grinding 
down the initially 650 µm thick slides to the thickness of 80-100 µm, and then polishing 
prior to staining. This process caused some debris to accumulate within the histological 
sections (Figure 3-8). Manual adjustments had to be made when sectioning the image, 
to exclude the debris particles from automatic thresholding.  
The exothermic polymerization of MMA can produce gas bubbles, which were evident 
in some slides. When these bubbles presented inside the region of interest, they were 






Figure 3-8 Histologic artefacts – stained debris. SB grafted site 
A. Overview. Red rectangle represents the positions of magnified B figure 








Figure 3-9 Gas bubbles artefacts.  
A. Overview. Red rectangle represents the positions of magnified B figure 











3.3.5 Summary of findings in descriptive histology 
The sinus mucosa presented as a characteristic, columnar, pseudostratified epithelium, 
and the mucosa was continuous in all but one specimen (grafted with Cone Oss®). The 
immediate submucosa was highly vascular.  
The surgical access defect was partially repaired in all specimens and fully repaired in 
two of them. The repairing bone was laminar, with thin trabeculae and extensive 
marrow spaces. The new bone appeared on both the antral and the facial aspects of the 
original bone plates. In most cases, the edges of the original bone plates were 
completely resorbed, remodelled, and no longer identifiable. 
Sites grafted with Bio-Oss® (BO) and Cone Oss® (CO) presented as augmented bell-
shaped areas, containing the residual grafting material and the new bone. The new 
bone appeared to be in direct contact with BO and CO particles. Evidence of 
osteoclastic resorption was found for BO residual graft. The BO particles were 
irregularly distributed, and some were incorporated into repairing bone walls, while 
CO particles were tightly packed in the centre of the augmented site.  
Most sites grafted with SmartBone® (SB), and all sites grafted with Cone® (CN), 
demonstrated no augmented area and no residual grafting material. In slides where 
some of the SB particles were retained, signs of resorption were evident, but osteoclasts 
were not present.  
Histologic artefacts, in the form of residual debris from polishing and bubbles, were 
present in multiple specimens; however, they could be easily masked by software and 




3.4 Histomorphometric analysis 
Two coronal sections representing the centre of each experimental site were chosen to 
measure the fraction of hard tissues within the ROI. The mean between the two 
sections was used as the representative value for each experimental site. 
The CN and SB grafted sites failed to demonstrate augmentation. Therefore no ROI 
was defined for them, and no statistical analysis was performed. 
3.4.1 New bone, residual graft and connective tissue fractions 
The connective tissue occupied the majority of the ROI for both BO (72%) and CO 
(82%). The residual grafting material occupied similar areas for BO (17%) and CO 
(18%). However, BO grafted sites on average demonstrated more than twice as much 
new bone in the ROI (10% for BO versus 4% for CO). Despite the absolute differences, 
the Wilcoxon signed rank test failed to demonstrate statistical significance between 
groups (p = 0.11). The standard deviation suggests a large variability of outcomes in 
both groups. 
The areas of new bone, residual graft, and connective tissue are presented in Table 3-3 
for each experimental site. 
Table 3-3 Mean fractions of hard tissue in the ROI by treatment modality 
Treatment 
modality 
Residual graft, % 
(SD) 
New bone, % 
(SD) 
Connective tissue, % 
(SD) 
Bio-Oss®, n=10 16% (10%) 9% (9%) 75% (14%) 
Cone Oss®, n=10 17% (15%) 4% (5%) 79% (20%) 





The data distribution is represented as a boxplot in Figure 3-10. 
 
Figure 3-10 Hard and soft tissue fractions for Bio-Oss® (BO) and Cone Oss® (CO).  
Note the overlap of the boxplots for the residual graft and connective tissue. The large standard 
deviation and small sample size obliterate the difference in NB between BO and CO groups. 
 
In 3 BO sites and 5 CO sites the new bone failed to form in the augmented submucosa. 
If only the specimens with more than zero new bone formation are analyzed, the data 
variability will be reduced (Figure 3-11), which is demonstrated by lower standard 
deviations (Table 3-4). However, even in this case, the discrepancy for the new bone 
formation between CO and BO would remain ~2-fold (Table 3-4). The Wilcoxon signed 
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rank test fails to demonstrate statistically significant differences between groups. The 
statistical analysis, in this case, is based on 4 specimens only, due to the use of paired 
samples. 
 Table 3-4 Mean fractions of hard tissue in the ROIs with more than zero new bone 
Treatment 
modality 
Residual graft, % 
(SD) 
New bone, % 
(SD) 
Connective tissue, % 
(SD) 
Bio-Oss®, n=7 21% (5%) 13% (8%) 66% (6%) 
Cone Oss®, n=5 29% (10%) 8% (5%) 63% (18%) 
p-value n=4 † 0.465 1.000 0.465 
† - when 2 BO and 5 CO sites omitted, only 4 specimens could be used for the paired Wilcoxon 




Figure 3-11 Tissue fractions for Bio-Oss® (BO) and Cone Oss® (CO) with more than 
zero new bone formation. 
The intra-group variability is smaller than in Figure 3-10.The mean for the new bone areas is 
closer between CO and BO groups when the cases with no NB are excluded.  
 
3.4.2 Augmentation height 
The height of augmentation was measured for BO and CO (Table 3-5). The average 
height was almost identical for both BO and CO. Average height-to-width ratio for CO 
was twice as high as for BO sites, meaning that graft particles were held tighter 




Table 3-5 Augmentation height 
 Height, mm (SD) 
n=10 
Height/width ratio (SD) 
n=7 † 
BO 2.74 mm (2.01 mm) 0.34 (0.20) 
CO 2.75 mm (2.65 mm) 0.58 (0.34) 
p 0.878 0.128 
† - the sites with failed augmentations were excluded from analysis 
3.4.3 Reliability and consistency 
The consistency of measurements of histomorphometric analysis was assessed using 
the help from the examiner that did not otherwise participate in this study. Ten 
specimens of BO and CO were randomly selected, then the examiners assessed: 
1. The total augmented area as specified in section 2.5.2.1 
2. The fraction occupied by NB, RG and CT in the pre-defined area of interest. 
Intraclass correlation coefficient (ICC) of assessments was calculated using two-way 
mixed model and absolute agreement type. Excellent correlation, as defined by 
Cicchetti (1994)317, was demonstrated for all measurements, the results are presented 
in Table 3-6. 
Table 3-6 Inter-examiner agreement 
Measurement Intraclass correlation coefficient 
Total area of ROI 0.995 
Residual graft 0.968 
Connective tissue 0.985 
New bone 0.994 
Less than 0.40—poor agreement; between 0.40 and 0.59—fair; between 0.60 and 0.74—good; 
between 0.75 and 1.00—excellent. 
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The principal examiner assessed the same set of ten specimens two months prior to 
inter-examiner agreement test. The data from the earlier and later assessments were 
compared for intra-examiner consistency using ICC. Excellent correlation317 was 
demonstrated for all measurements; the results are presented in Table 3-7 
Table 3-7 Intra-examiner correlation 
Measurement Intraclass correlation coefficient 
Total area of ROI 1.000 
Residual graft 0.999 
Connective tissue 1.000 
New bone 0.990 
Less than 0.40—poor agreement; between 0.40 and 0.59—fair; between 0.60 and 0.74—good; 
between 0.75 and 1.00—excellent. 
ICC scores are influenced by data variability. Higher ICC scores can be achieved when 
assessing highly variable outcomes. Some of the specimens selected for inter-examiner 
agreement tests demonstrated failed augmentation with zero new bone and residual 
graft areas. Zeros in data-set sites may have increased the data variability and 
artificially increased the ICC scores. We calculated ICC for inter- and intra-examiner 
agreement omitting the failed augmentation sites (Table 3-8, Table 3-9). Both intra-





Table 3-8 Inter-examiner agreement, successfully augmented sites only 
Measurement Intraclass correlation coefficient 
Total area of ROI 0.989 
Residual graft 0.951 
Connective tissue 0.961 
New bone 0.814 
Less than 0.40—poor agreement; between 0.40 and 0.59—fair; between 0.60 and 0.74—good; 
between 0.75 and 1.00—excellent. 
 
Table 3-9 Intra-examiner agreement, successfully augmented sites only 
Measurement Intraclass correlation coefficient 
Total area of ROI 1.000 
Residual graft 0.997 
Connective tissue 0.998 
New bone 0.989 
Less than 0.40—poor agreement; between 0.40 and 0.59—fair; between 0.60 and 0.74—good; 




3.4.4 Summary of findings in histomorphometric analysis 
At 16 weeks of healing the sites grafted with SmartBone® (SB) and Cone® (CN) have 
failed to demonstrate augmentation and new bone formation, therefore no ROI was 
defined for them, and no histomorphometric analysis was performed. 
Bio-Oss® (BO) and Cone Oss® (CO) grafted sites on average demonstrated similar 
fractions of the residual grafting material and the connective tissue. Despite 
demonstrating on average twice as large an area of the new bone, BO grafted sites did 
not differ statistically from CO grafted sites. The data was highly variable between 
specimens. In the present animal model, CO demonstrated equivalent new bone 






Chapter 4. Discussion 
4.1 Introduction 
The present study aimed to test three novel bone substitutes for sinus grafting against 
a well-studied xenograft serving as a positive control. The study objective was to 
analyze the outcomes of sinus grafting, histologically and histomorphometrically, 
using a well-established sheep animal model. The sheep model  for sinus grafting was 
developed by Haas et al.121. It was adopted and previously used by our institution281.  
4.2 Discussion of study outcomes 
In this section, we will discuss the results of the current study, compare them to the 
evidence derived from previous studies in other animal and human models, and 
discuss their clinical relevance. 
4.2.1 Summary of primary outcomes 
After 16 weeks of healing, the sites grafted with Cone® (CN) and SmartBone ® (SB) 
failed to demonstrate augmentation. The grafting material had completely 
disappeared from the majority of CN and SB grafted sites, leading to the collapse of 
the Schneiderian membrane (SM). No extra-skeletal bone was formed in the grafted 
area. The SB graft resorption was evident in three surgical sites where remnants of 
grafting material remained; however, no cells resembling osteoclasts, and no 
formations resembling Howship’s lacunae, were found on the surface of the graft. We 
may hypothesize that SB particles were not lost to osteoclastic resorption, but rather 
underwent enzymatic dissolution in the extracellular matrix.  
The BO and CO particles remained in the augmented space beneath the SM, and new 
extra-skeletal bone formed around these particles in the majority of surgical sites. The 
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newly formed bone was deposited directly onto the surface of BO and CO particles 
with the bone-graft complex formation. These histologic findings provide evidence for 
biocompatibility and osteoconductive properties of CO and BO. 
No statistically significant difference was found for histomorphometric outcomes 
between CO and BO.  
4.2.2 Histologic picture 
After 16 weeks of healing, for all treatment modalities, the repair of bony walls of the 
sinus was still incomplete for most surgical sites. The surgical defect of 10 mm in the 
sheep maxilla is not a critical size defect318. Therefore it is expected to heal completely 
given more healing time. The healing of the access window is seldom reported in the 
literature concerning sinus floor elevation. In a recent study using monkeys, one access 
window after 3 months and two after 6 months of healing appeared to be closed by 
newly formed bone, while the remainder were partially healed113.   
In my study, CN collagen completely disappeared from all but three experimental 
sites, where the degenerate remnants of the material were still present within the sinus 
submucosa. CN consists of non-cross-linked equine collagen. It was developed to be 
used in alveolar ridge preservation (ARP) procedures. The rationale of placing a 
collagen cone into fresh extraction sockets is to stabilize the blood clot. Collagen 
resorbs in 4-8 weeks after implantation in rats, the resorption rate depends in part on 
cross-linking density of the collagen319, 320. As the successful sinus floor augmentation 
requires that a space beneath the elevated Schneiderian membrane be maintained to 
permit new bone formation, we may conclude that the resorption of CN material 
occurred too rapidly, leading to the premature collapse of augmented space.  
Sponges made of bovine collagen were used as controls in a goat SFE model286. The 
authors reported a continuous reduction of augmented volume in the sites grafted with 
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collagen while the test sites (grafted with collagen soaked with Bone Morphogenic 
Protein) remained stable. Ahn et al. (2011)321 used collagen sponges (Zimmer™ 
Collaplug®) for sinus floor elevation through a lateral approach, in a clinical case series 
study on thirteen patients. In their study, the sites failed to demonstrate clinically 
relevant new bone formation.  Although in my study the collagen cone was also 
ineffective for SFE, the information from CN sites was still useful as a contrast to CO 
grafted sites, as CO consists of the same equine non-cross-linked collagen, but is filled 
with alloplastic filler. 
Similarly to CN, SB particles disappeared completely from most sites at 16 weeks post-
implantation, with Schneiderian membrane collapse and no new extra-skeletal bone 
formation. It is not clear why the SB grafting material underwent such a quick 
resorption. It is manufactured from deproteinized bovine bone mineral (DBBM) and a 
composition of two polymers: polylactic acid (PLA) and poly-ε-caprolactone (PCL) as 
copolymer.  
PLA has multiple biomedical applications including resorbable sutures, membranes 
and scaffolds. The degradation of PLA and copolymers is well documented for both in 
vitro and in vivo322-324. The addition of PCL to the composition is thought to slow down 
the rate of resorption of PLA and to improve its mechanical properties325, 326. As humans 
and animals lack the enzyme to degrade PLA and PCL, the resorption proceeds via 
hydrolysis, rather than enzymatic degradation327, 328. The hydrolysis of these materials 
is complex and is still not entirely understood. During degradation, they are thought 
to gradually lose fragments from the surface; these fragments break up into even 
smaller oligomers that are soluble in the extra-cellular matrix328. However, 
unpredictable bulk hydrolysis and quick resorption can sometimes be registered in-
vivo for certain PLA-PCL co-polymers329.  
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By changing the polymer composition, manufacturers can modify the resorption rate 
to suit the specific situation. In a clinical case series, Scarano et al. (2006) performed 
SFE in 94 patients with nine different grafting materials, including Bio-Oss®, 
autologous bone and poly-glycolic-poly-lactic acid copolymer (PLA-PGA). The 
biopsies were retrieved during implant placement in the grafted sites after 6 months. 
On histologic examination, this polymer appeared to be substituted by the newly 
formed bone (NB). NB constituted on average 33% ± 2.1%, marrow spaces 59% ± 2.3%, 
while residual PLA-PGA occupied 3% ± 2.1% of augmented sites176. Apparently, not all 
degradable polymers will be suited for SFE, although some may be efficient.  
To date, only limited amount of empirical data has been gathered concerning the 
resorption of a specific formulation of DBBM combined with PLA-PCL complex. In a 
study by Petrici, the manufacturer of SB used a mathematical model for predicting the 
resorption rate of the material and stated it should be adequate for slow resorption and 
creeping substitution by the bone330. This was not confirmed by the empirical findings 
from my study.  
Another series of in-vitro, in-vivo studies investigating biocompatibility and toxicity 
of SB was published by the same group331. This series included two case reports of 
human patients. The authors used SB for vertical ridge augmentation and guided bone 
regeneration prior to implant placement. The biopsy was harvested from one of the 
patients at a 4-month time-point during the implant placement. The histologic 
investigation confirmed the presence of residual graft in direct contact with newly 
formed bone.  
Another small-scale clinical case series study was recently published295: the authors 
performed lateral SFE in five patients with SB as grafting material. The implants were 
placed 4, 6, 7 and 9 months post-grafting and biopsies were retrieved. At 4 months SB 
was found to occupy 12% of the specimen; at 6 and 7 months, 0.5%; and at 9 months, 
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SB disappeared completely. Unlike in my study, the authors found that the new bone 
was replacing the graft, reaching 67% of the specimen area at 9 months. The small 
sample size of this study did not allow for statistical analysis of the results. 
We may hypothesize that in our model, increased pH or temperature of the inflamed 
healing wound may have accelerated hydrolysis of the polymer coating, leading to 
inflammation-driven resorption of SB in the earlier stages of healing. A word should 
also be spoken about the bovine-derived deproteinized matrix of SB. It is treated via 
acid attack at a low temperature304. The non-sintered (low-temperature deproteinized) 
materials are thought to be resorbed at the higher rate196. If this is true for the SB mineral 
content, it could have also contributed to its quick resorption and disappearance.  
NB formation was documented around the particles of both BO and CO. The NB was 
deposited directly on the surface of the particles with no interposing tissues, 
confirming that BO and CO are both biocompatible and have osteoconductive 
properties.  
The bone type was mostly lamellar, suggesting that the grafted site was relatively 
mature. In a previous study using the same model281, the sinuses grafted with BO 
demonstrated a similar histologic picture after 12 weeks of healing. In a recent 
publication by Alayan et al. (2016)7, the researchers documented an increase in the 
lamellar bone fraction from 8 to 16 weeks of healing. In another study, after 12 and 26 
weeks, sheep maxillary sites grafted with Straumann™ Bone Ceramic® and then 
restored with an implant showed mature trabecular bone enveloping the graft 
particles283. The observations from my study confirm the principle of the pattern for 
early bone development presented earlier332, where the formation of highly organized 




In my study, most of the BO particles seemed dispersed within the augmented site, 
without bone connecting between them. This is in line with the available histologic 
pictures from other studies7 272 using the same animal model. In a case series with 
human participants, the BO granules seemed to be more interconnected; however, this 
finding wasn’t quantified188. In a study by Haas, Donath et al. (1998)121, extensive bone 
formation around the particles of BO did not influence the bone contact with the 
implants that were placed in the grafted site. Phillip et al. (2014) found that the use of 
a graft filler enabled the bone to implant contact in the sheep sinus model after 26 
weeks; however, the percentage of bone formed within the grafted site was not 
quantified283.  
In my study, Howship’s resorption lacunae were found on some BO particles, which 
is in line with previous reports333, 334. It is known that osteoclastic resorption of BO 
happens at a slow pace, as the residual graft fraction was documented to decrease with 
time335. The extent of the osteoclastic resorption of BO is, however, unclear. BO particles 
have been shown histologically to persist in the grafted site for years after 
implantation162, 334. The BO persistence in the grafted sites was shown to delay healing 
in a dog extraction sites model335. The authors commented that bone enveloping the 
xenograft might be considered a special type of foreign body reaction, which in the 
case of SFE may serve the purpose of maintaining the extra-skeletal space for the NB 
formation. Persistence of the BO was effective in supporting bone in-growth; however, 
we are unable to comment on the pace or the extent of BO resorption based on the 
single time-point in my study. 
In the CO grafted sites, the granules of biphasic calcium phosphate (BCP) were tightly 
packed beneath the elevated Schneiderian membrane. New bone bridged between 
some of the granules in exactly half of the sites, the other half being devoid of new bone 
formation in the region of interest. The literature provides extensive evidence for 
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biocompatibility and osteoconductive properties of BCP in animals161 and humans204, 
296, 336. My study confirms the previous findings concerning biocompatibility and 
osteoconductivity, albeit overall performance of the material seemed to be inferior 
compared to the previous reports. 
We found no evidence of osteoclastic resorption for CO particles at the 16-week time-
point. Our findings contrast with the reports in the literature. Ohayon (2014)336 and 
Froum et al. (2008)337 found evidence for osteoclastic cells at the surface of the residual 
graft from human augmented sinus biopsies. While TCP alone is known for its quick 
and complete resorption in ECM, the biphasic, TCP-HA alloplast does not resorb as 
readily 161. The study of Phillip et al. (2014)283 used TCP/HA biphasic granules in the 
sheep sinus. After 26 weeks, there was some evidence of surface resorption of the 
granules; however, the presence of osteoclasts was not specifically identified (personal 
communication).  
It is possible that in my study the osteoclasts were present on the CO surface, but were 
not identified. Frenken et al. (2010)338 used osteoclast-specific TRAP staining to detect 
osteoclasts. TRAP-stained cells were found in small quantities on the surface of the 
biphasic TCP-HA alloplast (Straumann Bone Ceramic ®).  
We did not quantify inflammation in my study. The histologic method that we used 
does not allow for adequate immune cell recognition. Future studies may include 
paraffin-embedded sections stained with H&E, which are better suited for this type 
analysis.  
4.2.3 Histomorphometric outcomes 
In my study, the newly formed bone occupied 9% of the region of interest (ROI) in the 
sites grafted with BO. A previous study by our institution using Biomet 3i™ Endobon® 
(DBBM) in the sheep sinus also showed that 9.5% of the ROI was filled with new bone 
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after 16 weeks282. However, these findings contrast sharply with the publications by 
other groups. In a recent study using a similar sheep model, the new bone area with 
BO was reported to be much higher after 16 weeks of healing - up to 50%7. In human 
trials, the amount of newly formed bone during the first year in cases treated with 
maxillary sinus augmentation using BO varies from 8% to 42%166, 289.   
The sites grafted with CO demonstrated 4% new bone formation in the ROI. No other 
animal or human trials have investigated formulations that match CO (an alloplast 
consisting of 40:60% TCP:HA in a collagen cone), however similar graft material 
composed of biphasic 40:60% TCP:HA without the collagen matrix has been 
documented in human206, 337, 338 and animal trials161, 339. The NB area was reported to be 
between 20-30%, which contradicts our findings. We found that half of the CO sites 
did not develop new bone at all. If only the sites with some new bone formation were 
analyzed, the average NB fraction would have constituted 8%, which would have been 
lower than the figures reported in the literature.  
Whilst the NB fraction is an important histologic outcome, its clinical significance is 
not well understood. The mineralised content of type Ⅳ bone in humans was 
demonstrated to be 28%46. In the present study, the sites grafted with BO and CO 
corresponded with a very poor-quality bone. Pull-out tests correlate increased bone 
fraction with increased pull-out forces340. It is not known what percentage of vital bone 




4.3 Discussion of the model and the method 
In this section, we will outline the validity of the research method and the study 
limitations. 
4.3.1 Animal model 
4.3.1.1 Animal heterogeneity  
For this study, eleven sheep were purchased from a commercially available flock. The 
experimental animals were not inbred and therefore were genetically heterogeneous 
study subjects.  
The heterogeneity can impact graft-host interactions, the rate of bone healing, recovery 
from the surgery and reactions to medication, all of which leads to high variability of 
outcomes. Indeed, in this study, the standard deviation was substantial in all 
histomorphometric parameters. While the access window was only partially repaired 
in most sites, in one sheep (419), the antral wall of 3 out of 4 surgical sites (SB, CN, CO) 
was completely bridged, which may demonstrate faster bone healing rate in this 
animal. 
On the other hand, the experimental results from heterogenous population could be 
applied to the human population (which is also heterogenic) with greater confidence. 
In my study, we accounted for heterogeneity between the subjects by using the animal 
(rather than the experimental site) as a statistical unit. 
4.3.1.2 Sinus anatomy in sheep 
Ideally, a research model should exactly mimic the clinical situation in the human 
edentulous posterior maxilla, where a partially resorbed alveolus is overlying the thin 
cortical bony floor of the sinus. The maxillary sinus should be lined with a Schneiderian 
membrane, and there should be sufficient space in the sinus cavity to allow a clinically 
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relevant graft volume to be placed. Sheep sinus anatomy is considered sufficiently 
similar to that of humans in otolaryngology284 and surgical training341. Estaca et al. 
(2008) 230 performed a fresh sheep head dissection and stated that the lateral wall of the 
sheep sinus is relatively thin and easily trephined, resembling a situation in the human 
edentulous posterior maxilla.  
The sinus wall in sheep can be reached by an extra-oral or intra-oral route. Intra-oral 
access requires a previous surgical vestibular dissection230, 342-344. As this may complicate 
the recovery from surgery and cause unnecessary suffering for the animals, the extra-
oral access was chosen. However, extra-oral access is not representative of the clinical 
situation in humans and extrapolation should be made cautiously. 
4.3.1.3 Bone healing and graft incorporation in sheep 
The consolidation of the graft is a normal bone repair modified by the presence of the 
graft. The bone microstructure in sheep is somewhat different from that in humans: 
young adult sheep mostly have primary bone: plexiform structures of woven and 
cortical bone combined together345. Also, the lamellar bone in 3-4-year-old ewes is 
organized in brick-like layers without a central artery, rather than in Haversian 
cylinder-like structures346. In my study, we saw the plexiform repair of the antral walls. 
The bone that formed around the BO and CO particles was also resembling a woven-
lamellar complex with plexiform structure. It is difficult to assess how these differences 
in sheep bone morphology and repair impact the applicability of the model on the 
human population. 
The animals were killed after 16 weeks of healing. It is possible that more of the NB 
would have formed in the grafted site given more time. The 16-week healing period 
was chosen to produce comparable outcomes with other groups that used sheep as SFE 
model7, 276, 297. The healing rate in sheep is faster than in humans 278. Using a critical size 
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defect ovine model, Duncan (2005)29 has evaluated that 16 weeks of healing in sheep 
should correspond to 21 weeks of healing in humans, which was stated as an 
acceptable healing time for sinus floor elevation. 
Normal body temperature in sheep is 38.3 – 39.9˚C (www.merckvetmanual.com). The 
difference of 2 - 3˚C can influence the rate of hydrolysis of degradable polymer 
materials347, 348, leading to a faster resorption rate. This could have led to a faster 
resorption of PLA-PCL coated DBBM (SmartBone®) that we tested in my study. 
4.3.2 Surgical procedure 
The objective of sinus floor elevation (SFE) is to provide a recipient bed for implant 
placement. In many studies, the implants were placed concomitant with SFE to 
investigate implant-related outcomes, such as bone-to-implant contact126, 283, 340, 349. 
Concomitant placement of implants may influence healing and graft consolidation. 
They can stabilize the grafting site by providing a rigid anchor. Boyne et al. (1993)238 
placed implants in a primate sinus and found clear differences in healing around the 
different thread and apical configurations of identical TPS implants. Less bone formed 
at the apical end of open-ended and deep-threaded implants, while significantly more 
bone contacted the apex of otherwise identical round-ended implants. While the extent 
of the implant impact on the grafted site healing is unclear, my study was designed to 
reveal the process of graft consolidation and not the impact of bone substitutes on the 
osseointegration of dental implants. 
Our first animal failed to recover from surgery. This complication was not related to 
the sinus surgery, but rather to prolonged operating time. Two research projects, our 
SFE study and the alveolar ridge preservation study by another group300 were using 
the same animals, which prolonged the procedure time. Measures were undertaken to 
shorten the operating time, and the operators experienced a steep learning curve with 
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the procedures. Subsequent animals were operated on more quickly and recovered 
with no complications.  
Due to financial constraints and unavailability of dedicated facilities, we performed 
sinus grafting procedures without prior radiographic investigation of individual sinus 
anatomy of each animal. Doing so may increase the risk of intra-surgical complications, 
such as SM perforations, severing big vessels and unfavourable sinus anatomy. Indeed, 
we were forced to make one additional osteotomy due to constricted sinus space; we 
detected and repaired four SM perforations.  
In our model, the surgical sites were covered with resorbable collagen membranes. 
Although frequently used in human lateral SFE procedures, the evidence for their use 
mostly comes from animal research. Barone et al. (2013)350 did not find significant 
histological differences between the membrane group and uncovered control. A recent 
systematic review failed to arrive at definitive recommendations 253. The 
documentation concerning the use of barrier membranes in ovine SFE model is scarce. 
Alayan et al. (2016)7 used a porcine collagen membrane, Bio-Gide ® to cover the access 
windows, but his study did not include any control sites that were not covered by a 
membrane. A previous study by our group also used barrier membranes with no 
controls281. The advantage of a barrier membrane in conjunction with a graft of BO in 
an ovine model was described by Adeyemo et al. (2008)351, albeit in a mandibular site. 
Soft tissue encapsulation of BO particles was observed when the membrane was 
dislodged from the site.  
In my study, there were three surgical sites with small (less than 5 mm) Schneiderian 
membrane perforations. In one animal, these were grafted with CO, CN and SB, and 
in another animal, the site was grafted with BO. The perforations were repaired using 
the Loma Linda pouch technique, as previously described311. The histological results 
for the BO site with a repaired membrane demonstrated irregularity in SM and limited 
112 
 
augmentation volume. The CO site histology demonstrated the complete failure of 
augmentation with no residual grafting particles. Hence, in my study, the Loma Linda 
pouch technique failed to protect the grafted site and prevent medial displacement of 
grafting material. Some authors have described the reduced bone formation and 
compromised implant survival rates with resorbable membrane repair of 
perforations352, 353. No randomized studies in humans are available to substantiate the 
claim about the efficacy of sinus membrane perforations repair. In a recently published 
randomized animal study, the authors question the necessity for sinus membrane 
repair354. 
In order to standardize the grafting procedures, we used the same measured amount 
of grafting materials for all experimental sites. This enabled us to compare the grafting 
sites with more confidence; however, this is not representative of the clinical situation, 
where the amount of grafting material is changed depending on the desired extent of 
augmentation, and the individual site anatomy. Also, when the inferior portion of the 
sinus is filled with grafting material, it creates a protected space for regeneration where 
the bone ingrowth may occur from three directions: medial, inferior and lateral. In our 
surgical model, only one direction was available for bone ingrowth, thereby creating 
“one wall defect” and possibly reducing the rate of graft consolidation. 
The CN and CO grafting materials formulations that were used in this study are 
primarily intended for alveolar ridge preservation. Their conical shape is supposed to 
fit easily into the fresh extraction socket. The standardized quantity of pre-formed 
grafting material is also useful for research purposes. However, for SFE the handling 
of the conical-shaped grafting material is problematic. The operator has only limited 
control over the direction and the extent of graft placement. A gel-like or mouldable 
putty substrate which could adapt itself to the shape of the sinus, but still prevent the 
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dispersion of the particles of the grafting material, would have been more suited for 
SFE procedures.  
4.3.3 Sources of bias 
There were a number of possible sources of bias within the study that could have 
influenced the outcomes. 
4.3.3.1 Randomization, allocation concealment, blinding 
There was no allocation concealment and operator blinding implemented in the study. 
Instead, a predefined set of biomaterials was used for all the animals. This eliminated 
the allocation bias, but not the possible operator bias.  
A single examiner trimmed the specimens, selected ground sections and analyzed all 
digitized microscopic images. It was impossible to blind the examiner for the type of 
biomaterial that was used in every specific site, due to obvious histologic differences 
between the biomaterials. To partially alleviate the possibility of examiner bias, inter-
examiner comparisons were conducted with an independent examiner that was not 
part of the research group. 
4.3.3.2 Specimen sectioning and histologic slide selection 
In my study, we used embedded un-demineralised sections for histologic analysis. 
This technique is relatively simple and readily reproducible. The sections closest to the 
central part of the graft were selected based on radiographic imaging of the specimens. 
Between five to ten sections were cut from each specimen. Two of these sections were 
ground, stained and analyzed. It is possible that the selected sections were not 
representative of the entire experimental site, hereby introducing bias. Also, a learning 
curve existed for the operator: some sections were destroyed in the processing and 
could not be assessed. We analyzed not one, but two non-consecutive sections from 
each site in order to partially overcome the risk of bias from section selection.  
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4.3.3.3 ROI selection and analysis 
The histomorphometric outcomes of the study depended on the selection of a region 
of interest (ROI) and its sectioning into the residual graft, new bone and connective 
tissue. We chose to include the entire augmented area into ROI but to exclude the new 
bone that repaired the antral walls. This was done to: 
1. Analyze the area relevant to implant placement 
2. Standardize the selection for all the specimens for reproducibility of results. 
Ideally, to overcome the risk of examiner bias and achieve a reproducible result, 
automatic image sectioning (by software) should be implemented. In my study, no 
reliable software was identified for automatic sectioning of coloured histologic images, 
in part due to differences in staining between histologic slides. Therefore, the selection 
of ROI and its sectioning into new bone, residual graft and connective tissue was done 
manually. This might introduce an additional bias and influence the study outcomes. 
4.3.4 Study limitations 
Certain limitations were inherent in my study design. First, despite more than two-
fold differences for new bone fraction between CO and BO, statistical significance was 
not achieved in my study. We speculated that my study had less than the adequate 
sample size. The previous study in an ovine model by our group281 was not quantitative 
and did not provide information on the numbers required to achieve statistical 
significance. For my study, we selected a sample size of eleven, based on previous but 
slightly different studies which included simultaneous implant placement. The 
considerations for selecting the sample size were described in section 2.1.4. 
No post-hoc power analysis was performed in this study. While questioning the 
sample size is legitimate, the post-hoc power analysis cannot provide further 
information as to desirable sample size. The results of post-hoc power calculations are 
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mathematically guaranteed to define any null-result study as underpowered. Based on 
the variability of my study data, we may speculate that larger sample size is required 
to achieve more clear-cut results. 
The definition of ROI and the image sectioning were done manually by the primary 
investigator, which possibly introduced bias. Ideally, the image analysis should be 
done automatically. Despite the advances in machine learning systems, currently, no 
software solution exists for sectioning coloured histologic images. We performed intra- 
and inter-examiner reliability tests to reduce the possibility of bias from the manual 
image sectioning. 
In this study, we could not analyze the extent of the repair of the surgical access 
windows. The original surgical defects became un-identifiable in multiple histological 
sections due to an exuberant bone repair. The surgical windows were not standardized 
due to our use of piezo-surgical instruments. In this study, the analysis of the repair of 
the surgical access window was not a primary objective. We believed that reducing the 
risk of SM perforations by using the piezo-surgical instruments would be more 
important than standardizing the surgical access size.  
Another limitation comes from using a single time-point for all experimental animals. 
While providing more power to the study, this did not offer any insights as to the pace 
of graft consolidation and resorption. We are unable to comment on whether the BO 
or CO reached the limit of their potential or whether they would have retained the 
augmented volume when given a longer follow-up. 
Finally, the extra-oral approach and the use of a standard amount of the grafting 
material are not representative of clinical practice of SFE. 
Given the study limitations and the inherently limited applicability of animal research 







The goal of my study was to evaluate three novel grafting materials for sinus floor 
elevation in a sheep model, using bovine xenograft (Geistlich Bio-Oss ®) as a positive 
control. The tested products were: 1) equine collagen (PARASORB Cone®), 2) bovine 
non-sintered xenograft with polymer coating (IBI™ Smartbone ®), 3) equine collagen 
cone filled with biphasic calcium phosphate (PARASORB Cone Oss®). After 
sacrificing all animals at the 16-week time-point, we evaluated histologic specimens 
for healing and graft consolidation patterns, carried out histomorphometric analysis 
and compared the tested materials with respect to the areas occupied by new bone, 
residual graft and connective tissue.  
One animal failed to recover from general anaesthesia and was lost to analysis. All sites 
in the remaining animals healed uneventfully. The access windows in sheep antral 
walls demonstrated signs of bony repair with primary plexiform bone. As this bone 
replaced, in part, the original cortical plates, it was impossible to determine the extent 
of repair of the access windows. 
At 16 weeks Cone ® and Smartbone ® disappeared from grafted sites, and the 
Schneiderian membrane collapsed. No extra-skeletal bone was formed in the 
augmented sites.  
Both Bio-Oss® and Cone Oss® produced augmentation and new extra-skeletal bone 
formation. The new bone with both Bio-Oss ® and Cone Oss ® was comparatively low, 
which may be a result of the specific animal model used or insufficient time allocated 
for graft consolidation. There were no statistically significant differences in the new 
bone formation, connective tissue or residual graft areas between Bio-Oss® and Cone 
Oss®. We noted that on average twice as much new bone formed for Bio-Oss® than 
for Cone Oss®, although the results were highly variable.  
118 
 
My study used a previously developed animal model for sinus grafting in sheep with 
the extra-oral approach. This was the first time that the equine collagen-based grafting 
materials (Cone® and Cone Oss®) and polymer reinforced bovine xenograft 
(SmartBone®) had been tested in a large animal model. 
The alloplastic filler of Cone Oss® is embedded in an equine collagen cone. While this 
makes handling of the alloplast easier, this formulation is less suitable for sinus floor 
elevation. The operator has only limited control over the direction and spread of the 
material. Gel- or putty-like mouldable matrix could be more suitable for sinus grafting 




4.5 Recommendations for future research 
Based on my study, we cannot recommend the use of the collagen Cone® or the 
particulate SmartBone® for sinus grafting. Studies could be conducted concerning 
different implementations of these materials, such as alveolar ridge preservation for 
Cone® or vertical ridge augmentation for SmartBone®. Also, an in-vitro investigation 
of the osteoclastic and hydrolytic resorption of SmartBone® could help to clarify the 
reasons for its disappearance from the grafted sinuses in my study. 
The repair of the surgical access window after sinus floor elevation procedures is not 
adequately studied in the literature. The relationship between the window repair and 
the extent of the new bone formation in the grafted site could be further investigated. 
We discovered, that in the sheep model the margins of original surgical defects become 
un-identifiable histologically. A standardization of surgical access size could be 
considered to analyze the extent of the repair quantitatively: 
1. By using standard-size trephine to create a surgical window. This approach 
bears more risk for Schneiderian membrane perforation by the trephine. 
2. By using standard-size trephine after creating the initial non-standard access 
with piezo-tomes and elevating the Schneiderian membrane. This approach 
provides more control and less risk of perforating the membrane, which can be 
kept away from the trephine. 
3. By using histologic markers such as staples or sutures through the residual 
sinus walls. This approach, however, introduces a foreign body which could 
alter the process of wound healing and graft incorporation.  
This study assessed the outcomes at a single time-point to increase it’s power. This 
limited our ability to comment on healing trends, rates of new bone formation and 
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graft resorption. Future research could implement several time-points to investigate 
the extent and the rate of resorption of Cone Oss®. 
Sinus floor elevation is performed to facilitate implant placement. Additional research 
is recommended to: 
1. Quantify the impact of implant placement on the histologic outcomes of 
grafting. The sites grafted with Cone Oss® with and without concomitant 
implant placement could be histomorphometrically assessed.  
2. Investigate the relationship between new bone formation in grafted sites, bone-
to-implant contact and implant survival.   
Finally, a biphasic composition of Cone Oss® could be further explored. An advantage 
of a completely synthetic material is its potential to be customized to a specific clinical 
demand. While the ideal ratio of hydroxyapatite and tricalcium phosphate was 
challenging to determine for general use161, it is possible that a ratio other than 60/40 
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Chemical reagents used 
Distilled Water (H2O), purified via reverse osmosis unit (RiOs™ unit, Millipore Intertech, 
USA) 
Xylene, C6H4(CH3)2, (Ajax Finechem Pty Ltd, New Zealand) 
Ethanol, C2H5OH, (High grade, Absolute Ethanol, Thermo Fisher Scientific, USA) 
10% Natural Buffered Formalin (NBF), (BioLab Ltd, New Zealand)  
Methyl methacrylate 99% (MMA), (Sigma Aldrich, USA) 
Xylene, C6H4(CH3)2, (Ajax Finechem Pty Ltd, New Zealand)  
Concentrated Hydrochloric Acid (HCl), (100317.2500, Merck, Germany)  
Di-Ammonium Oxalate Monohydrate, (1.01190.1000, Merck, Germany)  
Phosphate Buffered Saline (PBS), (Gibco™, Invitrogen Corporation, NZ) 
3, 3’ diaminobenzidine (DAB), (Sigma D3939, Sigma Aldrich, USA) 
 
Equipment used 
Mectron® Piezosurgery 2 ultrasonic unit (Henry Schein Shalfoon™, Auckland NZ) 
Electrosurgical unit (NeoMed™ 3000A ESU, Solid State Electrosurgery Unit, USA 
Sinus membrane dissectors (Sinus Kit, Osstem™, Korea) 
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Accutom, cutting machine, (Struers, Ballerup Denmark) 
Gendex dental systems, (Monza, Italy) 
Tegra-Pol, polishing machine (Struers, Ballerup, Denmark) 
Silicon Carbide Paper, Grades 180-4000 (Struers, Ballerup, Denmark)  
Incubating/shaking machine (Multitron®, Infors HT, Switzerland) 
RiOs™ wall mounted water distillation unit, (Millipore Intertech, USA) 
APES (3-aminopropyltriethoxysilane) coated slides (Lab Scientific, Inc., USA).  








































1:2 (to effect) 
2% Mepivicaine 






2 x 2.2 ml cartridges 
around surgical site at 












5 ml around surgical site 
at completion of surgery 





Intramuscular 5 ml once/day for 3 
days following surgery 
0.2% w/v 
chlorhexidine 
gluconate solution  
Antiseptic Mouthrinse rinse once a day with 






Resin for embedding 
Ingredients 
Methyl methacrylate (Catalogue number M55909, Sigma Aldrich, USA) Benzoyl peroxide 
(Catalogue number 517909, Sigma Aldrich, USA) Dibutyl phthalate (Catalogue number 
524980, Sigma Aldrich, USA) Xylene, (Ajax Finechem Pty Ltd, New Zealand) 
Method for MMA I 
4 parts Methyl methacrylate 
1% Benzoyl peroxide 
1 Part Dibutyl phthalate 
Method for MMA II 
4 parts Methyl methacrylate 
0.5% Benzoyl peroxide 
1 part Dibutyl phthalate 
Method for MMA III 
4 parts Methyl methacrylate 
1% Benzoyl peroxide 
1 part Dibutyl phthalate  
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MMA Embedding protocol 
Immerse specimens, previously dehydrated in ethanol, in xylene for 4 days in fume 
cupboard on a rotating platform. Change to fresh xylene after 2 days. 
Wash specimens in methyl methacrylate (MMA) monomer. 
Transfer specimens to MMA I for 2 days in fume cupboard on a rotating platform. 
Fill glass jars with MMA III to one-third height, and place in a light-proof plastic container 
partially filled with water. Leave undisturbed at room temperature for 2-3 days until set. 
Immerse specimens in MMA II for 2 days in fume cupboard on a rotating platform. 
Retrieve each specimen and its identification tag from the histological cassette. Place the 
specimen and the tag flat in an individual glass jar with a pre-set MMA III base. Fill the 
jar with fresh MMA III, and tightly close the lid. 
Place glass jars in a half-filled water bath in the light-proof plastic container. Leave 
undisturbed at room temperature for at least 2 days, until fully set.  
Staining with MacNeal’s Tetrachrome / Toluidine Blue solution 
Solution A 
0.5g Methylene blue (Catalogue number 15943 Merck, Germany) 
0.8g Azur II (Catalogue number 9211 Merck, Germany) 
0.1g Methyl violet 2B (Catalogue number M 0527Sigma Aldrich, USA) 




Stir with magnetic stirrer until no precipitate seen Leave for 12 hours at 50°C then 3 days 
at 37°C  
Solution B 
Toluidine blue in 100ml distilled water + 1.0g borax 
Solution A+B 
10ml Solution A 
5ml Solution B 
85ml distilled water 
Staining protocol 
Place slide in 20% ethanol in Coplin jar 
Place Coplin jar in ultrasonic bath for 5 minutes 
Replace ethanol with 0.1% formic acid 
Place Coplin jar in ultrasonic bath for 5 minutes 
Wash slide with tap water 
Cover section on slide with Solution A+B for 5 minutes 
Rinse slide with distilled water for 5 minutes 


























Appendix Ⅳ – Histological data 
Histomorphometric data 






























409 ConeOss RP3 36.580 13.660 37.3% 3.860 10.6% 19.060 52.1% 7.530 5.080 2.450 32.5% 5.530 6.901 
409 ConeOss RP4 28.461 10.633 37.4% 3.993 14.0% 13.835 48.6% 7.346 4.260 3.086 42.0% 4.900 6.461 
413 ConeOss RA1 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 3.917 N/A N/A 0.000 0.000 
413 ConeOss RA2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.674 N/A N/A 0.000 0.000 
414 ConeOss RP6 43.692 3.913 9.0% 0.451 1.0% 39.328 90.0% 9.980 0.620 9.360 93.8% 6.552 6.219 
414 ConeOss RP5 24.974 5.178 20.7% 0.142 0.6% 19.654 78.7% N/A 1.646 N/A N/A 6.548 5.784 
415 ConeOss LA5 6.080 0.371 6.1% 0.000 0.0% 5.709 93.9% 7.829 5.092 2.737 35.0% 0.374 5.078 
415 ConeOss LA3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 11.724 6.276 5.448 46.5% 0.000 0.000 
416 ConeOss LP5 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 0.000 N/A N/A 0.000 0.000 
416 ConeOss LP3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 7.415 1.307 6.108 82.4% 0.000 0.000 
417 ConeOss RA3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 
 
N/A N/A 0.000 0.000 
417 ConeOss RA6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 8.293 N/A N/A 0.000 0.000 
418 ConeOss RP1 28.520 8.362 29.3% 1.675 5.9% 18.483 64.8% 5.260 2.797 2.463 46.8% 4.792 6.505 
418 ConeOss RP2 31.476 9.068 28.8% 2.377 7.6% 20.031 63.6% 7.460 0.285 7.175 96.2% 4.792 7.924 
419 ConeOss LA6 30.008 8.302 27.7% 3.933 13.1% 18.630 62.1% N/A 0.000 N/A 100.0% 4.407 7.870 
419 ConeOss LA5 24.913 6.372 25.6% 4.024 16.2% 14.517 58.3% N/A 0.000 N/A N/A 3.676 8.134 
420 ConeOss LP1 36.710 15.875 43.2% 1.099 3.0% 22.396 61.0% N/A 5.078 N/A N/A 4.642 8.376 
420 ConeOss LP3 33.295 11.036 33.1% 3.029 9.1% 19.230 57.8% 9.692 5.178 4.514 46.6% 4.389 8.337 
421 ConeOss RA3 7.757 1.514 19.5% 0.000 0.0% 6.243 80.5% N/A 1.421 N/A N/A 1.244 4.126 


































409 BioOss RA1 22.386 6.277 28.0% 2.758 12.3% 13.351 59.6% 6.490 3.220 3.270 50.4% 4.518 6.949 
409 BioOss RA3 17.542 5.070 28.9% 0.299 1.7% 12.173 69.4% 5.879 3.791 2.088 35.5% 4.285 8.214 
413 BioOss LP4 6.063 0.776 12.8% 1.950 32.2% 3.337 55.0% 7.869 0.000 7.869 100.0% 1.297 5.737 
413 BioOss LP3 8.224 1.039 12.6% 2.187 26.6% 4.998 60.8% 8.469 3.654 4.815 56.9% 0.904 10.057 
414 BioOss RA7 43.824 7.612 17.4% 5.190 11.8% 31.022 70.8% 7.533 3.825 3.708 49.2% 4.921 13.407 
414 BioOss RA3 38.724 6.607 17.1% 3.119 8.1% 28.998 74.9% 5.504 1.925 3.579 65.0% 4.406 10.965 
415 BioOss RP1 22.784 5.052 22.2% 2.757 12.1% 14.975 65.7% N/A 0.000 N/A 100.0% 3.637 8.360 
415 BioOss RP3 19.354 3.480 18.0% 0.196 1.0% 15.678 81.0% N/A 0.000 N/A 100.0% 3.238 7.613 
416 BioOss RA3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.380 5.241 4.139 44.1% 0.000 0.000 
416 BioOss RA1 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.579 4.040 5.539 57.8% 0.000 0.000 
417 BioOss LP3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 12.096 9.008 3.088 25.5% 0.000 0.000 
417 BioOss LP5 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.181 6.365 2.816 30.7% 0.000 0.000 
418 BioOss RA9 75.793 22.309 29.4% 8.117 10.7% 45.367 59.9% 11.293 4.814 6.479 57.4% 5.812 14.549 
418 BioOss RA6 72.286 15.486 21.4% 5.468 7.6% 51.332 71.0% 9.229 6.446 2.783 30.2% 6.106 15.321 
419 BioOss RP1 10.853 3.277 30.2% 0.270 2.5% 7.698 70.9% 8.575 3.410 5.165 60.2% 1.432 12.512 
419 BioOss RP2 36.062 8.198 22.7% 3.110 8.6% 24.754 68.6% 8.576 4.483 4.093 47.7% 4.081 13.586 
420 BioOss LA3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 7.364 N/A N/A 0.652 0.000 
420 BioOss LA1 11.598 1.506 13.0% 0.000 0.0% 10.092 87.0% 11.166 6.551 4.615 41.3% 1.890 5.094 
421 BioOss LP5 20.285 3.769 18.6% 2.981 14.7% 17.826 87.9% 7.482 3.035 4.447 59.4% 3.259 10.166 



































409 Cone LP5 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 2.000 N/A N/A 0.000 0.000 
409 Cone LP6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.749 N/A N/A 0.000 0.000 
413 Cone LA2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 2.430 N/A N/A 0.000 0.000 
413 Cone LA1 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.131 N/A N/A 0.000 0.000 
414 Cone LP4 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 3.645 N/A N/A 0.000 0.000 
414 Cone LP6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 7.562 3.003 4.559 60.3% 0.000 0.000 
415 Cone RA6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A N/A N/A N/A 0.000 0.000 
415 Cone RA2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.348 N/A N/A 0.000 0.000 
416 Cone RP3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.348 N/A N/A 0.000 0.000 
416 Cone RP3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.480 4.814 4.666 49.2% 0.000 0.000 
417 Cone LA2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.692 5.317 4.375 45.1% 0.000 0.000 
417 Cone LA2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 2.294 N/A N/A 0.000 0.000 
418 Cone LP1 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 2.754 N/A N/A 0.000 0.000 
418 Cone LP2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 13.213 6.045 7.168 54.2% 0.000 0.000 
419 Cone RA4 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 5.889 N/A N/A 0.000 0.000 
419 Cone RA6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 5.941 N/A N/A 0.000 0.000 
420 Cone RP3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.574 N/A N/A 0.000 0.000 
420 Cone RP2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 2.000 N/A N/A 0.000 0.000 
421 Cone LA3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.749 N/A N/A 0.000 0.000 





































409 SmartBone LA3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 2.707 N/A N/A N/A N/A 
409 SmartBone LA2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.713 0.732 8.981 92.5% N/A N/A 
413 SmartBone RP1 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 0.000 N/A 100.0% N/A N/A 
413 SmartBone RP2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 3.881 N/A N/A N/A N/A 
414 SmartBone LA1 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 3.469 N/A N/A N/A N/A 
414 SmartBone LA4 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 11.679 7.587 4.092 35.0% N/A N/A 
415 SmartBone LP6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 7.133 N/A N/A N/A N/A 
415 SmartBone LP3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 0.000 N/A 100.0% N/A N/A 
416 SmartBone LA3 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 5.013 N/A N/A N/A N/A 
416 SmartBone LA2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.780 2.535 7.245 74.1% N/A N/A 
417 SmartBone RP2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.869 4.250 5.619 56.9% N/A N/A 
417 SmartBone RP5 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.271 N/A N/A N/A N/A 
418 SmartBone LA3 7.653 0.135 1.8% 0.457 6.0% 7.061 92.3% 8.281 3.372 4.909 59.3% 1.217 3.743 
418 SmartBone LA6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 5.013 N/A N/A N/A N/A 
419 SmartBone LP1 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.780 2.535 7.245 74.1% N/A N/A 
419 SmartBone LP2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 9.869 4.250 5.619 56.9% N/A N/A 
419 SmartBone LP2 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 4.271 N/A N/A N/A N/A 
420 SmartBone RA5 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% 12.377 6.805 5.572 45.0% N/A N/A 
420 SmartBone RA6 0.000 0.000 0.0% 0.000 0.0% 0.000 100.0% N/A 6.742 N/A N/A N/A N/A 






Principal examiner, March 2017 

















409 BioOss RA3 17.501 3.005 0.634 21.1% 0.000 0.0% 2.371 78.9% 
409 ConeOss RP4 29.021 7.166 3.060 42.7% 0.830 11.6% 3.276 45.7% 
414 ConeOss RP6 43.78 8.160 2.158 26.4% 0.000 0.0% 6.002 73.6% 
414 BioOss RA3 38.694 4.610 0.540 11.7% 0.041 0.9% 4.029 87.4% 
416 BioOss RA3 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 
416 ConeOss LP5 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 
418 BioOss RA9 75.695 4.748 0.267 5.6% 0.080 1.7% 4.401 92.7% 
418 ConeOss RP1 28.45 4.800 0.271 5.6% 0.423 8.8% 4.106 85.5% 
420 BioOss LA3 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 





Principal examiner, May 2017 

















409 BioOss RA3 17.542 3.074 0.567 18.4% 0.000 0.0% 2.507 81.6% 
409 ConeOss RP4 28.461 6.966 2.972 42.7% 1.001 14.4% 2.993 43.0% 
414 ConeOss RP6 43.692 8.169 2.100 25.7% 0.000 0.0% 6.069 74.3% 
414 BioOss RA3 38.724 4.650 0.615 13.2% 0.051 1.1% 3.984 85.7% 
416 BioOss RA3 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 
416 ConeOss LP5 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 
418 BioOss RA9 75.793 4.595 0.255 5.5% 0.074 1.6% 4.266 92.8% 
418 ConeOss RP1 28.52 4.913 0.280 5.7% 0.399 8.1% 4.234 86.2% 
420 BioOss LA3 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 





























409 BioOss RA3 17.555 3.244 0.601 18.5% 0.000 0.0% 2.643 81.5% 
409 ConeOss RP4 25.773 6.808 3.990 58.6% 0.807 11.9% 2.011 29.5% 
414 ConeOss RP6 41.635 8.871 2.550 28.7% 0.000 0.0% 6.321 71.3% 
414 BioOss RA3 36.81 5.711 0.822 14.4% 0.099 1.7% 4.790 83.9% 
416 BioOss RA3 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 
416 ConeOss LP5 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 
418 BioOss RA9 66.896 4.831 0.100 2.1% 0.645 13.4% 4.086 84.6% 
418 ConeOss RP1 27.763 4.307 0.341 7.9% 0.431 10.0% 3.535 82.1% 
420 BioOss LA3 0.000 0.000 0.000 0.0% 0.000 0.0% 0.000 0.0% 




Appendix Ⅴ – Radiograph of the resin-embedded 
specimens 
 
